New	O
immunosuppressive	O
drug	O
PNU156804	O
blocks	O
IL-2	B-protein
-dependent	O
proliferation	O
and	O
NF-kappa	O
B	O
and	O
AP-1	O
activation	O
.	O

We	O
had	O
previously	O
shown	O
that	O
the	O
drug	O
undecylprodigiosin	O
(	O
UP	O
)	O
blocks	O
human	B-cell_type
lymphocyte	I-cell_type
proliferation	O
in	O
vitro	O
.	O

We	O
have	O
now	O
investigated	O
the	O
mechanism	O
of	O
action	O
of	O
a	O
new	O
analogue	O
of	O
UP	O
,	O
PNU156804	O
,	O
which	O
shows	O
a	O
more	O
favorable	O
activity	O
profile	O
than	O
UP	O
in	O
mice	O
.	O

We	O
demonstrate	O
here	O
that	O
the	O
biological	O
effect	O
of	O
PNU156804	O
in	O
vitro	O
is	O
indistinguishable	O
from	O
UP	O
:	O
PNU156804	O
blocks	O
human	B-cell_type
T	I-cell_type
cell	I-cell_type
proliferation	O
in	O
mid-late	O
G1	O
,	O
as	O
determined	O
by	O
cell	O
cycle	O
analysis	O
,	O
expression	O
of	O
cyclins	B-protein
,	O
and	O
cyclin-dependent	B-protein
kinases	I-protein
and	O
retinoblastoma	O
phosphorylation	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
PNU156804	O
does	O
not	O
block	O
significantly	O
the	O
induction	O
of	O
either	O
IL-2	B-protein
or	O
IL-2R	B-protein
alpha-	I-protein
and	I-protein
gamma-chains	I-protein
but	O
inhibits	O
IL-2	B-protein
-dependent	O
T	O
cell	O
proliferation	O
.	O

We	O
have	O
investigated	O
several	O
molecular	O
pathways	O
that	O
are	O
known	O
to	O
be	O
activated	O
by	O
IL-2	B-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O

We	O
show	O
that	O
PNU156804	O
does	O
not	O
inhibit	O
c-myc	O
and	O
bcl-2	O
mRNA	O
induction	O
.	O

On	O
the	O
other	O
hand	O
,	O
PNU156804	O
efficiently	O
inhibits	O
the	O
activation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
transcription	O
factors	O
.	O

PNU156804	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
is	O
due	O
to	O
the	O
inhibition	O
of	O
the	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
and	O
I	B-protein
kappa	I-protein
B-beta	I-protein
.	O

PNU156804	O
action	O
is	O
restricted	O
to	O
some	O
signaling	O
pathways	O
;	O
it	O
does	O
not	O
affect	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
PMA	O
in	O
T	B-cell_type
cells	I-cell_type
but	O
blocks	O
that	O
induced	O
by	O
CD40	B-protein
cross-linking	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

We	O
conclude	O
that	O
the	O
prodigiosin	O
family	O
of	O
immunosuppressants	O
is	O
a	O
new	O
family	O
of	O
molecules	O
that	O
show	O
a	O
novel	O
target	O
specificity	O
clearly	O
distinct	O
from	O
that	O
of	O
other	O
immunosuppressive	O
drugs	O
such	O
as	O
cyclosporin	O
A	O
,	O
FK506	O
,	O
and	O
rapamycin	O
.	O

X	NULL
Boldly	NULL
GolnVivo	NULL
``	NULL
``	NULL
BioLegend®	NULL
#	NULL
m	NULL
meJournal	NULL
of	NULL
New	NULL
Immunosuppressive	NULL
Drug	NULL
PNU156804	NULL
..	NULL
--	NULL
=	NULL
``	NULL
``	NULL
'Immur1010	NULL
gy	NULL
Blocks	NULL
IL-2-Dependent	NULL
Proliferation	NULL
and	NULL
NF-	NULL
xB	NULL
and	NULL
AP-1	NULL
Activation	NULL
This	NULL
inf	NULL
tion	NULL
i	NULL
t	NULL
Alessandra	NULL
Mortellaro	NULL
,	NULL
Simona	NULL
Songia	NULL
,	NULL
Paola	NULL
Gnocchi	NULL
,	NULL
of	NULL
£1	NULL
:	NULL
le	NULL
(	NULL
Tani	NULL
;	NULL
i	NULL
)	NULL
;	NULL
Is	NULL
current	NULL
as	NULL
Mario	NULL
Ferrari	NULL
,	NULL
Chiara	NULL
Fornasiero	NULL
,	NULL
Roberto	NULL
D'Alessio	NULL
,	NULL
Anna	NULL
Isetta	NULL
,	NULL
Francesco	NULL
Colotta	NULL
and	NULL
Josée	NULL
Golay	NULL
J	NULL
Immunol	NULL
1999	NULL
;	NULL
162:7102-7109	NULL
;	NULL
;	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/162/12/7102	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
50	NULL
articles	NULL
,	NULL
18	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/162/12/7102.full	NULL
#	NULL
ref-list-1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
New	NULL
Immunosuppressive	NULL
Drug	NULL
PNU156804	NULL
Blocks	NULL
IL-2-Dependent	NULL
Proliferation	NULL
and	NULL
NF-B	NULL
and	NULL
AP-1	NULL
Activation	NULL
'	NULL
Alessandra	NULL
Mortellaro	NULL
,	NULL
*	NULL
Simona	NULL
Songia	NULL
,	NULL
*	NULL
Paola	NULL
Gnocchi	NULL
,	NULL
'	NULL
Mario	NULL
Ferrari	NULL
,	NULL
'	NULL
Chiara	NULL
Fornasiero	NULL
,	NULL
'	NULL
Roberto	NULL
D'Alessio	NULL
,	NULL
``	NULL
Anna	NULL
Isetta	NULL
,	NULL
'	NULL
Francesco	NULL
Colotta	NULL
,	NULL
'	NULL
``	NULL
and	NULL
Josée	NULL
We	NULL
had	NULL
previously	NULL
shown	NULL
that	NULL
the	NULL
drug	NULL
undecylprodigiosin	NULL
(	NULL
UP	NULL
)	NULL
blocks	NULL
human	NULL
lymphocyte	NULL
proliferation	NULL
in	NULL
vitro	NULL
.	NULL

We	NULL
have	NULL
now	NULL
investigated	NULL
the	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
a	NULL
new	NULL
analogue	NULL
of	NULL
UP	NULL
,	NULL
PNU156804	NULL
,	NULL
which	NULL
shows	NULL
a	NULL
more	NULL
favorable	NULL
activity	NULL
profile	NULL
than	NULL
UP	NULL
in	NULL
mice	NULL
.	NULL

We	NULL
demonstrate	NULL
here	NULL
that	NULL
the	NULL
biological	NULL
effect	NULL
of	NULL
PNU156804	NULL
in	NULL
vitro	NULL
is	NULL
indistinguishable	NULL
from	NULL
UP	NULL
:	NULL
PNU156804	NULL
blocks	NULL
human	NULL
T	NULL
cell	NULL
proliferation	NULL
in	NULL
mid-late	NULL
G	NULL
,	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
cell	NULL
cycle	NULL
analysis	NULL
,	NULL
expression	NULL
of	NULL
cyclins	NULL
,	NULL
and	NULL
cyclin-dependent	NULL
kinases	NULL
and	NULL
retinoblastoma	NULL
phosphorylation	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
show	NULL
that	NULL
PNU156804	NULL
does	NULL
not	NULL
block	NULL
significantly	NULL
the	NULL
induction	NULL
of	NULL
either	NULL
IL-2	NULL
or	NULL
IL-2R	NULL
a-	NULL
and	NULL
y-chains	NULL
but	NULL
inhibits	NULL
IL-2-dependent	NULL
T	NULL
cell	NULL
proliferation	NULL
.	NULL

We	NULL
have	NULL
investigated	NULL
several	NULL
molecular	NULL
pathways	NULL
that	NULL
are	NULL
known	NULL
to	NULL
be	NULL
activated	NULL
by	NULL
IL-2	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

We	NULL
show	NULL
that	NULL
PNU156804	NULL
does	NULL
not	NULL
inhibit	NULL
c-myc	NULL
and	NULL
bel-2	NULL
mRNA	NULL
induction	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
PNU156804	NULL
efficiently	NULL
inhibits	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
NF-B	NULL
and	NULL
AP-1	NULL
transcription	NULL
factors	NULL
.	NULL

PNU156804	NULL
inhibition	NULL
of	NULL
activation	NULL
is	NULL
due	NULL
to	NULL
the	NULL
inhibition	NULL
of	NULL
the	NULL
degradation	NULL
of	NULL
IxB-a	NULL
&	NULL
and	NULL
IxB-	NULL
.	NULL

PNU156804	NULL
action	NULL
is	NULL
restricted	NULL
to	NULL
some	NULL
signaling	NULL
pathways	NULL
;	NULL
it	NULL
does	NULL
not	NULL
affect	NULL
NF-B	NULL
activation	NULL
by	NULL
PMA	NULL
in	NULL
T	NULL
cells	NULL
but	NULL
blocks	NULL
that	NULL
induced	NULL
by	NULL
CD40	NULL
cross-linking	NULL
in	NULL
B	NULL
lymphocytes	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
the	NULL
prodigiosin	NULL
family	NULL
of	NULL
immunosuppressants	NULL
is	NULL
a	NULL
new	NULL
family	NULL
of	NULL
molecules	NULL
that	NULL
show	NULL
a	NULL
novel	NULL
target	NULL
specificity	NULL
clearly	NULL
distinct	NULL
from	NULL
that	NULL
of	NULL
other	NULL
immunosuppressive	NULL
drugs	NULL
such	NULL
as	NULL
cyclosporin	NULL
A	NULL
,	NULL
FK506	NULL
,	NULL
and	NULL
rapamycin	NULL
.	NULL

The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
1999	NULL
,	NULL
162	NULL
;	NULL
7102-7109.	NULL
yelosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
has	NULL
proved	NULL
an	NULL
extremely	NULL
useful	NULL
and	NULL
potent	NULL
immunosuppressive	NULL
drug	NULL
in	NULL
organ	NULL
transplantation	NULL
and	NULL
is	NULL
also	NULL
employed	NULL
to	NULL
treat	NULL
some	NULL
autoimmune	NULL
diseases	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

However	NULL
its	NULL
deleterious	NULL
side	NULL
effects	NULL
,	NULL
in	NULL
particular	NULL
renal	NULL
toxicity	NULL
,	NULL
have	NULL
encouraged	NULL
the	NULL
search	NULL
for	NULL
new	NULL
immunosuppressive	NULL
compounds	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

Drugs	NULL
showing	NULL
a	NULL
different	NULL
mechanism	NULL
of	NULL
action	NULL
than	NULL
CsA	NULL
are	NULL
likely	NULL
to	NULL
be	NULL
good	NULL
candidates	NULL
for	NULL
combined	NULL
therapy	NULL
with	NULL
CsA	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
drugs	NULL
affecting	NULL
IL-2-dependent	NULL
signaling	NULL
should	NULL
be	NULL
of	NULL
particular	NULL
interest	NULL
,	NULL
not	NULL
only	NULL
for	NULL
their	NULL
potential	NULL
clinical	NULL
use	NULL
but	NULL
also	NULL
to	NULL
define	NULL
the	NULL
role	NULL
of	NULL
the	NULL
different	NULL
molecular	NULL
cascades	NULL
triggered	NULL
by	NULL
IL-2	NULL
in	NULL
T	NULL
cell	NULL
proliferation	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
described	NULL
the	NULL
biological	NULL
activity	NULL
of	NULL
a	NULL
new	NULL
immunosuppressive	NULL
drug	NULL
,	NULL
undecylprodigiosin	NULL
(	NULL
UP	NULL
)	NULL
,	NULL
on	NULL
human	NULL
T	NULL
and	NULL
B	NULL
lymphocytes	NULL
in	NULL
vitro	NULL
(	NULL
5	NULL
)	NULL
.	NULL

This	NULL
compound	NULL
was	NULL
encouraging	NULL
since	NULL
it	NULL
efficiently	NULL
inhibited	NULL
the	NULL
polyclonal	NULL
proliferation	NULL
of	NULL
primary	NULL
human	NULL
T	NULL
and	NULL
B	NULL
lymphocytes	NULL
induced	NULL
by	NULL
a	NULL
variety	NULL
of	NULL
Ca**-dependent	NULL
and	NULL
Ca**-indepen-dent	NULL
mitogens	NULL
.	NULL

It	NULL
also	NULL
completely	NULL
blocked	NULL
the	NULL
proliferation	NULL
and	NULL
immortalization	NULL
of	NULL
B	NULL
cells	NULL
by	NULL
EBV	NULL
.	NULL

At	NULL
a	NULL
concentration	NULL
fully	NULL
active	NULL
on	NULL
primary	NULL
lymphocytes	NULL
(	NULL
50	NULL
ng/m1	NULL
)	NULL
,	NULL
UP	NULL
did	NULL
not	NULL
affect	NULL
significantly	NULL
the	NULL
proliferation	NULL
of	NULL
transformed	NULL
leukemic	NULL
cell	NULL
lines	NULL
in	NULL
vitro	NULL
.	NULL

Fi-	NULL
*Department	NULL
of	NULL
Immunology	NULL
and	NULL
Cell	NULL
Biology	NULL
,	NULL
Istituto	NULL
Ricerche	NULL
Farmacologiche	NULL
Mario	NULL
Negri	NULL
,	NULL
Milan	NULL
,	NULL
Italy	NULL
;	NULL
and	NULL
*Department	NULL
of	NULL
Pharmacology	NULL
,	NULL
Pharmacia	NULL
and	NULL
Upjohn	NULL
Research	NULL
Center	NULL
,	NULL
Nerviano	NULL
,	NULL
Italy	NULL
Received	NULL
for	NULL
publication	NULL
October	NULL
13	NULL
,	NULL
1998	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
April	NULL
5	NULL
,	NULL
1999	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
adverfisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
'	NULL

J.G	NULL
.	NULL

is	NULL
a	NULL
Fellow	NULL
of	NULL
the	NULL
1997	NULL
Angelo	NULL
and	NULL
Angela	NULL
Valenti	NULL
Foundation	NULL
.	NULL

2	NULL
Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
Josée	NULL
Golay	NULL
,	NULL
Istituto	NULL
Ricerche	NULL
Farmacologiche	NULL
``	NULL
Mario	NULL
Negri	NULL
,	NULL
``	NULL
via	NULL
Eritrea	NULL
62	NULL
,	NULL
20157	NULL
Milan	NULL
,	NULL
Italy	NULL
.	NULL

E-mail	NULL
address	NULL
:	NULL
Golay	NULL
@	NULL
irfmn.mnegri.it	NULL
3	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
CsA	NULL
,	NULL
cyclosporin	NULL
A	NULL
;	NULL
UP	NULL
,	NULL
undecylprodigiosin	NULL
;	NULL
PI3-kinase	NULL
,	NULL
phosphatidylinositol	NULL
3'-kinase	NULL
;	NULL
PI	NULL
,	NULL
propidium	NULL
iodide	NULL
;	NULL
rhIL-2	NULL
,	NULL
recombinant	NULL
human	NULL
IL-2	NULL
;	NULL
SAC	NULL
,	NULL
Staphylococcus	NULL
aureus	NULL
Cowan	NULL
I	NULL
strain	NULL
bacteria	NULL
;	NULL
MAPK	NULL
,	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
;	NULL
ERK	NULL
,	NULL
extracellular	NULL
signal-related	NULL
kinase	NULL
;	NULL
MEKK-1	NULL
,	NULL
MAPK/	NULL
ERK	NULL
kinase	NULL
kinase-1	NULL
;	NULL
JNK	NULL
,	NULL
c-Jun	NULL
N-terminal	NULL
kinase	NULL
;	NULL
Jak	NULL
,	NULL
Janus	NULL
kinase	NULL
;	NULL
PKB	NULL
,	NULL
protein	NULL
kinase	NULL
B	NULL
;	NULL
cdk	NULL
,	NULL
cyclin-dependent	NULL
kinase	NULL
.	NULL

Copyright	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
nally	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
UP	NULL
on	NULL
the	NULL
induction	NULL
of	NULL
protooncogenes	NULL
and	NULL
cell	NULL
cycle	NULL
genes	NULL
had	NULL
shown	NULL
that	NULL
UP	NULL
had	NULL
a	NULL
different	NULL
mechanism	NULL
of	NULL
action	NULL
than	NULL
CsA	NULL
,	NULL
FK506	NULL
,	NULL
or	NULL
rapamycin	NULL
,	NULL
making	NULL
it	NULL
a	NULL
good	NULL
candidate	NULL
drug	NULL
for	NULL
combined	NULL
immunotherapy	NULL
with	NULL
these	NULL
agents	NULL
(	NULL
5	NULL
)	NULL
.	NULL

UP	NULL
,	NULL
however	NULL
,	NULL
has	NULL
never	NULL
been	NULL
developed	NULL
as	NULL
an	NULL
immunosuppressant	NULL
because	NULL
it	NULL
was	NULL
found	NULL
to	NULL
produce	NULL
too	NULL
severe	NULL
side	NULL
effects	NULL
in	NULL
vivo	NULL
(	NULL
Ref	NULL
.	NULL

5	NULL
and	NULL
Isetta	NULL
et	NULL
al	NULL
.	NULL

,	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

This	NULL
led	NULL
to	NULL
the	NULL
screening	NULL
for	NULL
UP	NULL
analogues	NULL
with	NULL
more	NULL
favorable	NULL
activities	NULL
in	NULL
vivo	NULL
.	NULL

The	NULL
analogue	NULL
PNU156804	NULL
showed	NULL
promising	NULL
activity	NULL
as	NULL
an	NULL
immunosuppressant	NULL
in	NULL
mice	NULL
.	NULL

In	NULL
particular	NULL
PNU156804	NULL
gave	NULL
a	NULL
2-	NULL
to	NULL
3-fold	NULL
more	NULL
favorable	NULL
ratio	NULL
of	NULL
effective	NULL
vs	NULL
lethal	NULL
dose	NULL
in	NULL
a	NULL
DTH	NULL
model	NULL
in	NULL
vivo	NULL
.	NULL

Also	NULL
it	NULL
showed	NULL
toxic	NULL
effects	NULL
in	NULL
vitro	NULL
on	NULL
resting	NULL
lymphocytes	NULL
or	NULL
cell	NULL
lines	NULL
at	NULL
30-fold	NULL
higher	NULL
doses	NULL
than	NULL
UP	NULL
(	NULL
Isetta	NULL
et	NULL
al	NULL
.	NULL

,	NULL
manuscript	NULL
in	NULL
preparation	NULL
)	NULL
.	NULL

This	NULL
compound	NULL
was	NULL
therefore	NULL
selected	NULL
for	NULL
further	NULL
studies	NULL
.	NULL

We	NULL
have	NULL
investigated	NULL
the	NULL
biological	NULL
effect	NULL
and	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
PNU156804	NULL
on	NULL
primary	NULL
human	NULL
lymphocytes	NULL
in	NULL
vitro	NULL
.	NULL

We	NULL
demonstrate	NULL
that	NULL
prodigiosins	NULL
are	NULL
a	NULL
new	NULL
class	NULL
of	NULL
immunosuppressive	NULL
molecules	NULL
that	NULL
efficiently	NULL
inhibit	NULL
IL-2-dependent	NULL
T	NULL
cell	NULL
proliferation	NULL
and	NULL
show	NULL
novel	NULL
molecular	NULL
targets	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Cells	NULL
and	NULL
cell	NULL
cultures	NULL
Human	NULL
primary	NULL
T	NULL
lymphocytes	NULL
were	NULL
obtained	NULL
from	NULL
buffy	NULL
coats	NULL
of	NULL
normal	NULL
volunteers	NULL
.	NULL

Briefly	NULL
,	NULL
mononuclear	NULL
cells	NULL
were	NULL
separated	NULL
on	NULL
a	NULL
Ficoll-Hypaque	NULL
gradient	NULL
(	NULL
Seromed	NULL
,	NULL
Berlin	NULL
,	NULL
Germany	NULL
)	NULL
,	NULL
and	NULL
lymphocytes	NULL
were	NULL
separated	NULL
from	NULL
monocytes	NULL
by	NULL
centrifugation	NULL
onto	NULL
50	NULL
%	NULL
isoosmotic	NULL
Percoll	NULL
(	NULL
Pharmacia	NULL
Fine	NULL
Chemicals	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
.	NULL

If	NULL
necessary	NULL
,	NULL
residual	NULL
monocytes	NULL
were	NULL
removed	NULL
by	NULL
1-h	NULL
adherence	NULL
onto	NULL
tissue	NULL
culture	NULL
petri	NULL
dishes	NULL
(	NULL
Falcon	NULL
,	NULL
Oxnard	NULL
,	NULL
England	NULL
)	NULL
in	NULL
complete	NULL
medium	NULL
.	NULL

The	NULL
resulting	NULL
lymphocyte	NULL
population	NULL
contained	NULL
1-2	NULL
%	NULL
CD14*	NULL
monocytes	NULL
,	NULL
6-10	NULL
%	NULL
CD20	NULL
B	NULL
lymphocytes	NULL
,	NULL
and	NULL
>	NULL
80	NULL
%	NULL
CD3+*	NULL
T	NULL
lymphocytes	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
indirect	NULL
immunofluores-cence	NULL
with	NULL
appropriate	NULL
mAbs	NULL
on	NULL
the	NULL
FACS	NULL
.	NULL

Resting	NULL
B	NULL
lymphocytes	NULL
were	NULL
purified	NULL
from	NULL
fresh	NULL
human	NULL
tonsils	NULL
,	NULL
obtained	NULL
from	NULL
routine	NULL
tonsillectomies	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Se-romed	NULL
)	NULL
,	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
(	NULL
HyClone	NULL
,	NULL
Steril	NULL
System	NULL
,	NULL
Logan	NULL
,	NULL
UT	NULL
)	NULL
,	NULL
glutamine	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Paisley	NULL
,	NULL
Scotland	NULL
)	NULL
,	NULL
and	NULL
50	NULL
g/ml	NULL
gen-tamicin	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
.	NULL

0022-1767/99/	NULL
$	NULL
02.00	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
Reagents	NULL
PHA	NULL
(	NULL
Murex	NULL
Diagnostics	NULL
,	NULL
Dartford	NULL
,	NULL
England	NULL
)	NULL
was	NULL
used	NULL
at	NULL
1	NULL
pg/ml	NULL
.	NULL

Killed	NULL
Staphylococcus	NULL
aureus	NULL
Cowan	NULL
I	NULL
(	NULL
SAC	NULL
)	NULL
strain	NULL
bacteria	NULL
(	NULL
Calbiochem	NULL
)	NULL
were	NULL
used	NULL
at	NULL
0.005	NULL
%	NULL
.	NULL

PMA	NULL
was	NULL
obtained	NULL
from	NULL
Sigma	NULL
and	NULL
used	NULL
at	NULL
3	NULL
ng/ml	NULL
.	NULL

UP	NULL
and	NULL
PNU156804	NULL
were	NULL
obtained	NULL
by	NULL
a	NULL
fully	NULL
synthetic	NULL
process	NULL
(	NULL
D'Alessio	NULL
et	NULL
al	NULL
.	NULL

,	NULL
manuscript	NULL
in	NULL
preparation	NULL
)	NULL
.	NULL

Purified	NULL
anti-CD40	NULL
Ab	NULL
(	NULL
clone	NULL
626.1	NULL
)	NULL
was	NULL
a	NULL
kind	NULL
gift	NULL
of	NULL
Dr.	NULL
D.	NULL
Vercelli	NULL
(	NULL
DIBIT	NULL
,	NULL
Hospital	NULL
San	NULL
Raffaele	NULL
,	NULL
Milan	NULL
,	NULL
Italy	NULL
)	NULL
.	NULL

Cell	NULL
stimulations	NULL
,	NULL
proliferation	NULL
,	NULL
and	NULL
cytotoxicity	NULL
assays	NULL
Primary	NULL
lymphocytes	NULL
were	NULL
plated	NULL
at	NULL
1-2	NULL
X	NULL
10	NULL
%	NULL
/ml	NULL
in	NULL
flasks	NULL
(	NULL
for	NULL
RNA	NULL
and	NULL
protein	NULL
extractions	NULL
)	NULL
or	NULL
in	NULL
quadruplicate	NULL
in	NULL
96-well	NULL
plates	NULL
(	NULL
Falcon	NULL
)	NULL
.	NULL

At	NULL
48	NULL
h	NULL
,	NULL
0.5	NULL
uCi	NULL
|HJthymidine	NULL
was	NULL
added	NULL
in	NULL
each	NULL
well	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
,	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
in	NULL
a	NULL
Titertek	NULL
cell	NULL
harvester	NULL
(	NULL
Ska-tron	NULL
,	NULL
Lyerbyen	NULL
,	NULL
Norway	NULL
)	NULL
12-16	NULL
h	NULL
later	NULL
.	NULL

For	NULL
IL-2-dependent	NULL
T	NULL
cell	NULL
proliferation	NULL
,	NULL
T	NULL
lymphocytes	NULL
were	NULL
stimulated	NULL
for	NULL
72	NULL
h	NULL
with	NULL
1	NULL
pg/ml	NULL
PHA	NULL
to	NULL
induce	NULL
expression	NULL
of	NULL
the	NULL
IL-2R	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
washed	NULL
and	NULL
replated	NULL
in	NULL
medium	NULL
containing	NULL
1	NULL
%	NULL
FCS	NULL
.	NULL

After	NULL
24	NULL
h	NULL
,	NULL
recombinant	NULL
human	NULL
IL-2	NULL
(	NULL
rhIL-2	NULL
;	NULL
Serono	NULL
,	NULL
Rome	NULL
,	NULL
Italy	NULL
)	NULL
was	NULL
added	NULL
at	NULL
200	NULL
U/ml	NULL
.	NULL

PNU156804	NULL
or	NULL
UP	NULL
were	NULL
added	NULL
at	NULL
the	NULL
indicated	NULL
concentrations	NULL
10	NULL
min	NULL
before	NULL
IL-2	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
30	NULL
min	NULL
or	NULL
4	NULL
h	NULL
after	NULL
addition	NULL
of	NULL
IL-2	NULL
.	NULL

Thymidine	NULL
incorporation	NULL
was	NULL
measured	NULL
at	NULL
48-60	NULL
h.	NULL
To	NULL
measure	NULL
cell	NULL
death	NULL
,	NULL
T	NULL
lymphocytes	NULL
were	NULL
stimulated	NULL
as	NULL
above	NULL
for	NULL
48	NULL
h.	NULL
Cells	NULL
were	NULL
then	NULL
stained	NULL
with	NULL
FITC-labeled	NULL
annexin	NULL
V	NULL
and	NULL
propidium	NULL
iodide	NULL
(	NULL
PT	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
Mannheim	NULL
,	NULL
Germany	NULL
)	NULL
and	NULL
analyzed	NULL
on	NULL
a	NULL
FACScan	NULL
apparatus	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Cell	NULL
cycle	NULL
analysis	NULL
Monoparametric	NULL
cell	NULL
cycle	NULL
analysis	NULL
on	NULL
ethanol-fixed	NULL
cells	NULL
using	NULL
PI	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Analysis	NULL
was	NULL
done	NULL
on	NULL
at	NULL
least	NULL
10*	NULL
cells	NULL
using	NULL
a	NULL
FACStar	NULL
``	NULL
``	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
.	NULL

The	NULL
Baisch	NULL
method	NULL
was	NULL
used	NULL
to	NULL
assess	NULL
the	NULL
cell	NULL
cycle	NULL
phase	NULL
distribution	NULL
(	NULL
7	NULL
)	NULL
.	NULL

RNA	NULL
extraction	NULL
and	NULL
Northern	NULL
blots	NULL
RNA	NULL
was	NULL
extracted	NULL
by	NULL
standard	NULL
guanidium	NULL
isothiocyanate	NULL
and	NULL
cesium	NULL
chloride	NULL
gradient	NULL
purification	NULL
.	NULL

Twenty	NULL
micrograms	NULL
total	NULL
RNA	NULL
was	NULL
run	NULL
in	NULL
1	NULL
%	NULL
formaldehyde-agarose	NULL
gels	NULL
and	NULL
blotted	NULL
onto	NULL
GeneScreen	NULL
Plus	NULL
membranes	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

All	NULL
probes	NULL
were	NULL
labeled	NULL
with	NULL
*°P	NULL
by	NULL
standard	NULL
nick-translation	NULL
.	NULL

The	NULL
cDNA	NULL
probes	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
5	NULL
)	NULL
.	NULL

The	NULL
edk2	NULL
and	NULL
edk4	NULL
plasmids	NULL
used	NULL
as	NULL
probes	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
ATCC	NULL
,	NULL
Man-assas	NULL
,	NULL
VA	NULL
)	NULL
.	NULL

Western	NULL
blots	NULL
Western	NULL
blots	NULL
were	NULL
performed	NULL
essentially	NULL
as	NULL
described	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Cytoplasmic	NULL
extracts	NULL
were	NULL
loaded	NULL
and	NULL
run	NULL
in	NULL
8-12	NULL
%	NULL
SDS/polyacrylamide	NULL
gels	NULL
.	NULL

The	NULL
gels	NULL
were	NULL
electroblotted	NULL
onto	NULL
nitrocellulose	NULL
filters	NULL
(	NULL
Schleicher	NULL
&	NULL
Schuell	NULL
,	NULL
Dassel	NULL
,	NULL
Germany	NULL
)	NULL
for	NULL
3-5	NULL
h	NULL
at	NULL
35	NULL
V	NULL
,	NULL
according	NULL
to	NULL
standard	NULL
procedures	NULL
.	NULL

The	NULL
blots	NULL
were	NULL
incubated	NULL
first	NULL
in	NULL
blocking	NULL
solution	NULL
(	NULL
PBS	NULL
containing	NULL
5	NULL
%	NULL
nonfat	NULL
milk	NULL
powder	NULL
)	NULL
overnight	NULL
,	NULL
then	NULL
with	NULL
rabbit	NULL
antiserum	NULL
or	NULL
mouse	NULL
monoclonal	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

All	NULL
specific	NULL
Abs	NULL
used	NULL
for	NULL
Western	NULL
blots	NULL
were	NULL
from	NULL
Santa	NULL
Cruz	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Secondary	NULL
Abs	NULL
conjugated	NULL
to	NULL
HRP	NULL
were	NULL
from	NULL
Amersham	NULL
and	NULL
used	NULL
at	NULL
1/1000	NULL
.	NULL

Between	NULL
each	NULL
incubation	NULL
,	NULL
the	NULL
blots	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
for	NULL
10	NULL
min	NULL
in	NULL
PBS	NULL
containing	NULL
0.5	NULL
%	NULL
NP4O0	NULL
.	NULL

Detection	NULL
was	NULL
performed	NULL
using	NULL
the	NULL
ECL	NULL
chemilu-minescence	NULL
system	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

EMSA	NULL
Cells	NULL
were	NULL
lysed	NULL
in	NULL
buffer	NULL
A	NULL
(	NULL
50	NULL
mM	NULL
KCI	NULL
,	NULL
0.1	NULL
%	NULL
NP40	NULL
,	NULL
25	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.8	NULL
)	NULL
,	NULL
1	NULL
mM	NULL
PMSF	NULL
,	NULL
10	NULL
pg/ml	NULL
leupeptin	NULL
,	NULL
20	NULL
ug/ml	NULL
aprotinin	NULL
,	NULL
and	NULL
100	NULL
uM	NULL
DTT	NULL
)	NULL
for	NULL
5	NULL
min	NULL
at	NULL
4°C	NULL
and	NULL
centrifuged	NULL
5	NULL
min	NULL
at	NULL
2500	NULL
rpm	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
nuclear	NULL
pellets	NULL
were	NULL
lysed	NULL
in	NULL
buffer	NULL
B	NULL
(	NULL
500	NULL
mM	NULL
KCI	NULL
,	NULL
25	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.8	NULL
)	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
and	NULL
100	NULL
wM	NULL
DTT	NULL
)	NULL
containing	NULL
protease	NULL
inhibitors	NULL
with	NULL
gentle	NULL
shaking	NULL
for	NULL
20	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
lysates	NULL
were	NULL
then	NULL
centrifuged	NULL
at	NULL
12,000	NULL
rpm	NULL
for	NULL
5	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
nuclear	NULL
extracts	NULL
were	NULL
dialyzed	NULL
for	NULL
2	NULL
h	NULL
at	NULL
4°C	NULL
against	NULL
buffer	NULL
C	NULL
(	NULL
50	NULL
mM	NULL
KCI	NULL
,	NULL
25	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.8	NULL
)	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
1	NULL
mM	NULL
PMSF	NULL
,	NULL
and	NULL
100	NULL
LM	NULL
DTT	NULL
)	NULL
.	NULL

Double-stranded	NULL
oligonucleotides	NULL
carrying	NULL
a	NULL
binding	NULL
site	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
from	NULL
the	NULL
HIV-1	NULL
promoter	NULL
)	NULL
and	NULL
for	NULL
AP-1	NULL
(	NULL
from	NULL
the	NULL
IL-8	NULL
promoter	NULL
)	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
NF-KB	NULL
,	NULL
dGGTCCAGAGGGGACTTITTCCGAGAGGC	NULL
;	NULL
AP-1	NULL
,	NULL
dGTGTGATGACTCAGGTTTCC	NULL
.	NULL

The	NULL
oligonucleotides	NULL
were	NULL
labeled	NULL
with	NULL
[	NULL
°P	NULL
]	NULL
dCTP	NULL
and	NULL
klenow	NULL
enzyme	NULL
.	NULL

For	NULL
binding	NULL
,	NULL
2-5	NULL
ug	NULL
nuclear	NULL
extract	NULL
was	NULL
bound	NULL
to	NULL
0.2	NULL
ng	NULL
probe	NULL
in	NULL
binding	NULL
buffer	NULL
(	NULL
40	NULL
mM	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
120	NULL
mM	NULL
KCl	NULL
,	NULL
8	NULL
%	NULL
Ficoll	NULL
400	NULL
,	NULL
4	NULL
mM	NULL
EDTA	NULL
,	NULL
2	NULL
mM	NULL
DTT	NULL
,	NULL
and	NULL
2	NULL
ug	NULL
poly	NULL
(	NULL
dIdC	NULL
)	NULL
)	NULL
for	NULL
30	NULL
min	NULL
.	NULL

In	NULL
supershift	NULL
experiments	NULL
,	NULL
2	NULL
pl	NULL
specific	NULL
Abs	NULL
was	NULL
added	NULL
.	NULL

7103	NULL
Results	NULL
PNU156804	NULL
inhibits	NULL
human	NULL
T	NULL
and	NULL
B	NULL
cell	NULL
proliferation	NULL
UP	NULL
,	NULL
the	NULL
first	NULL
identified	NULL
member	NULL
of	NULL
the	NULL
prodigiosin	NULL
family	NULL
,	NULL
showed	NULL
too	NULL
severe	NULL
side	NULL
effects	NULL
upon	NULL
prolonged	NULL
treatment	NULL
in	NULL
vivo	NULL
(	NULL
5	NULL
)	NULL
for	NULL
development	NULL
as	NULL
an	NULL
immunosuppressant	NULL
.	NULL

Screening	NULL
for	NULL
prodigiosin	NULL
analogues	NULL
with	NULL
a	NULL
more	NULL
favorable	NULL
activity	NULL
led	NULL
to	NULL
the	NULL
identification	NULL
of	NULL
PNU156804	NULL
,	NULL
whose	NULL
structure	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
together	NULL
with	NULL
that	NULL
of	NULL
UP	NULL
.	NULL

PNU156804	NULL
has	NULL
a	NULL
benzylic	NULL
substitution	NULL
in	NULL
place	NULL
of	NULL
methylic	NULL
substitution	NULL
on	NULL
the	NULL
oxydrylic	NULL
group	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
activity	NULL
and	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
PNU156804	NULL
on	NULL
human	NULL
T	NULL
lymphocytes	NULL
,	NULL
we	NULL
first	NULL
determined	NULL
its	NULL
capacity	NULL
to	NULL
inhibit	NULL
mitogen-induced	NULL
T	NULL
cell	NULL
or	NULL
B	NULL
cell	NULL
proliferation	NULL
in	NULL
comparison	NULL
with	NULL
UP	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

24	NULL
,	NULL
PNU156804	NULL
inhibited	NULL
by	NULL
up	NULL
to	NULL
90	NULL
%	NULL
the	NULL
proliferation	NULL
of	NULL
human	NULL
T	NULL
cells	NULL
stimulated	NULL
by	NULL
PHA	NULL
.	NULL

The	NULL
optimal	NULL
inhibitory	NULL
dose	NULL
was	NULL
200-300	NULL
ng/ml	NULL
,	NULL
compared	NULL
with	NULL
50	NULL
ng/ml	NULL
for	NULL
UP	NULL
.	NULL

Thus	NULL
a	NULL
4-	NULL
to	NULL
6-fold	NULL
higher	NULL
concentration	NULL
of	NULL
PNU156804	NULL
than	NULL
UP	NULL
is	NULL
required	NULL
.	NULL

Of	NULL
note	NULL
is	NULL
that	NULL
the	NULL
dose-response	NULL
curve	NULL
of	NULL
PNU156804	NULL
is	NULL
less	NULL
sharp	NULL
than	NULL
than	NULL
of	NULL
UP	NULL
.	NULL

PNU156804	NULL
also	NULL
inhibited	NULL
the	NULL
MLR	NULL
response	NULL
of	NULL
T	NULL
cells	NULL
,	NULL
with	NULL
a	NULL
similar	NULL
dose-response	NULL
curve	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
,	NULL
showing	NULL
that	NULL
inhibition	NULL
is	NULL
efficient	NULL
also	NULL
in	NULL
a	NULL
more	NULL
physiological	NULL
model	NULL
of	NULL
T	NULL
cell	NULL
response	NULL
and	NULL
is	NULL
not	NULL
specific	NULL
for	NULL
PHA	NULL
.	NULL

Similarly	NULL
,	NULL
PNU156804	NULL
efficiently	NULL
inhibited	NULL
SAC-induced	NULL
tonsillar	NULL
B	NULL
cell	NULL
proliferation	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
EBV-induced	NULL
B	NULL
cell	NULL
proliferation	NULL
and	NULL
immortalization	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Again	NULL
the	NULL
dose	NULL
response	NULL
curves	NULL
were	NULL
similar	NULL
to	NULL
those	NULL
obtained	NULL
in	NULL
PHA	NULL
stimulated	NULL
T	NULL
cells	NULL
.	NULL

We	NULL
verified	NULL
that	NULL
the	NULL
drug	NULL
PNU156804	NULL
did	NULL
not	NULL
induce	NULL
cell	NULL
death	NULL
by	NULL
microscopic	NULL
examination	NULL
at	NULL
different	NULL
times	NULL
and	NULL
by	NULL
quantifica-tion	NULL
of	NULL
cell	NULL
death	NULL
with	NULL
a	NULL
standard	NULL
method	NULL
that	NULL
detects	NULL
extracellular	NULL
phosphatidyl	NULL
serine	NULL
with	NULL
fluorescein-labeled	NULL
annexin	NULL
V	NULL
and	NULL
FACS	NULL
analysis	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
I	NULL
,	NULL
PNU156804	NULL
at	NULL
a	NULL
fully	NULL
active	NULL
concentration	NULL
(	NULL
300	NULL
ng/m	NULL
!	NULL
)	NULL

did	NULL
not	NULL
induce	NULL
a	NULL
significant	NULL
increase	NULL
in	NULL
either	NULL
apoptotic	NULL
or	NULL
necrotic	NULL
cells	NULL
above	NULL
that	NULL
induced	NULL
by	NULL
PHA	NULL
alone	NULL
.	NULL

Less	NULL
than	NULL
4	NULL
%	NULL
more	NULL
dead	NULL
cells	NULL
could	NULL
be	NULL
detected	NULL
in	NULL
presence	NULL
of	NULL
B.	NULL
PNU156804	NULL
C11H23	NULL
HCI	NULL
FIGURE	NULL
1	NULL
.	NULL

Structure	NULL
of	NULL
the	NULL
prodigiosin	NULL
analogue	NULL
PNU156804	NULL
.	NULL

The	NULL
structure	NULL
of	NULL
the	NULL
synthetic	NULL
compound	NULL
PNU156804	NULL
is	NULL
shown	NULL
in	NULL
comparison	NULL
with	NULL
that	NULL
of	NULL
UP	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
7104	NULL
J	NULL
>	NULL
Thymidine	NULL
uptake	NULL
(	NULL
x	NULL
10°	NULL
cpm	NULL
)	NULL
a	NULL
L	NULL
FIGURE	NULL
2	NULL
.	NULL

PNU156804	NULL
blocks	NULL
lym-	NULL
o	NULL
phocyte	NULL
proliferation	NULL
.	NULL

Human	NULL
primary	NULL
T	NULL
or	NULL
B	NULL
lymphocytes	NULL
were	NULL
stimulated	NULL
with	NULL
PHA	NULL
(	NULL
A	NULL
)	NULL
,	NULL
heterologous	NULL
T	NULL
lymphocytes	NULL
C	NULL
(	NULL
MLR	NULL
;	NULL
B	NULL
)	NULL
,	NULL
or	NULL
SAC	NULL
(	NULL
C	NULL
)	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
increasing	NULL
concentrations	NULL
of	NULL
UP	NULL
or	NULL
PNU156804	NULL
.	NULL

[	NULL
°H	NULL
]	NULL
Thymidine	NULL
incorporation	NULL
was	NULL
measured	NULL
at	NULL
48-66	NULL
h.	NULL
&	NULL
l=	NULL
]	NULL
O	NULL
<	NULL
]	NULL
v-	NULL
O	NULL
e	NULL
B	NULL
o	NULL
=	NULL
)	NULL
1	NULL
1	NULL
Thymidine	NULL
uptake	NULL
(	NULL
x	NULL
10°	NULL
cpm	NULL
)	NULL
No	NULL
2	NULL
.	NULL

T	NULL
lymphocytes	NULL
+	NULL
PHA	NULL
INHIBITION	NULL
OF	NULL
IL-2-DEPENDENT	NULL
SIGNALING	NULL
BY	NULL
PNU156804	NULL
B	NULL
co	NULL
a	NULL
MLR	NULL
(	NULL
~	NULL
&	NULL
1	NULL
-O-	NULL
PNU156804	NULL
-	NULL
@	NULL
-	NULL
UP	NULL
-O-	NULL
PNU156804	NULL
Drug	NULL
concentration	NULL
(	NULL
ng/m	NULL
!	NULL
)	NULL

Thymidine	NULL
uptake	NULL
(	NULL
x	NULL
10°	NULL
cpm	NULL
)	NULL
h	NULL
p	NULL
0	NULL
5	NULL
t	NULL
T	NULL
1	NULL
o	NULL
o	NULL
o	NULL
o	NULL
o	NULL
35	NULL
|	NULL
3	NULL
o	NULL
S3	NULL
|	NULL
5	NULL
3	NULL
&	NULL
<	NULL
in	NULL
a	NULL
<	NULL
6	NULL
®	NULL
Drug	NULL
concentration	NULL
(	NULL
ng/ml	NULL
)	NULL
B	NULL
lymphocytes	NULL
+	NULL
SAC	NULL
-O-	NULL
PNU156804	NULL
-	NULL
*-	NULL
up	NULL
2007	NULL
3007	NULL
4007	NULL
500	NULL
Drug	NULL
concentration	NULL
(	NULL
ng/ml	NULL
!	NULL
)	NULL

PNU156804	NULL
relative	NULL
to	NULL
its	NULL
absence	NULL
,	NULL
even	NULL
when	NULL
higher	NULL
concentrations	NULL
of	NULL
PNU156804	NULL
were	NULL
used	NULL
(	NULL
600	NULL
ng/m	NULL
!	NULL
)	NULL

.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
incubation	NULL
of	NULL
the	NULL
cells	NULL
overnight	NULL
with	NULL
staurosporine	NULL
as	NULL
a	NULL
control	NULL
led	NULL
to	NULL
a	NULL
3-	NULL
to	NULL
4-fold	NULL
increase	NULL
in	NULL
both	NULL
apoptotic	NULL
and	NULL
necrotic	NULL
cells	NULL
.	NULL

PNU156804	NULL
inhibits	NULL
T	NULL
cell	NULL
proliferation	NULL
in	NULL
mid-late	NULL
G	NULL
,	NULL
To	NULL
determine	NULL
the	NULL
cell	NULL
cycle	NULL
phase	NULL
of	NULL
inhibition	NULL
by	NULL
PNU156804	NULL
,	NULL
we	NULL
also	NULL
analyzed	NULL
the	NULL
DNA	NULL
content	NULL
of	NULL
human	NULL
T	NULL
lymphocytes	NULL
stimulated	NULL
with	NULL
PHA	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
PNU156804	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
entry	NULL
of	NULL
the	NULL
cells	NULL
in	NULL
the	NULL
S/G	NULL
,	NULL
/M	NULL
phases	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
induced	NULL
by	NULL
PHA	NULL
at	NULL
48	NULL
h	NULL
,	NULL
was	NULL
completely	NULL
blocked	NULL
by	NULL
PNU156804	NULL
.	NULL

These	NULL
data	NULL
show	NULL
that	NULL
PNU156804	NULL
inhibits	NULL
T	NULL
cell	NULL
activation	NULL
before	NULL
entry	NULL
into	NULL
S	NULL
phase	NULL
.	NULL

Table	NULL
I	NULL
.	NULL

Measurement	NULL
of	NULL
cell	NULL
death	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PNU156804®	NULL
Apoptotic	NULL
Necrotic	NULL
Total	NULL
Treatment	NULL
``	NULL
Cells®	NULL
(	NULL
%	NULL
)	NULL
Cells	NULL
``	NULL
(	NULL
%	NULL
)	NULL
_	NULL
Dead	NULL
``	NULL
(	NULL
%	NULL
)	NULL
PHA	NULL
13.2	NULL
5.0	NULL
18.2	NULL
PHA	NULL
+	NULL
PNU	NULL
(	NULL
300	NULL
ng/ml	NULL
)	NULL
12.8	NULL
9.8	NULL
21.6	NULL
PHA	NULL
+	NULL
PNU	NULL
(	NULL
600	NULL
ng/ml	NULL
)	NULL
17.3	NULL
4.4	NULL
21.7	NULL
PHA	NULL
+	NULL
staurosporine	NULL
``	NULL
53.5	NULL
24.8	NULL
78.3	NULL
``	NULL
The	NULL
background	NULL
positivity	NULL
of	NULL
untreated	NULL
cells	NULL
was	NULL
substracted	NULL
.	NULL

The	NULL
results	NULL
are	NULL
representative	NULL
of	NULL
two	NULL
separate	NULL
experiments	NULL
.	NULL

*	NULL
Cells	NULL
were	NULL
cultured	NULL
with	NULL
the	NULL
indicated	NULL
reagents	NULL
for	NULL
48	NULL
h	NULL
and	NULL
then	NULL
stained	NULL
with	NULL
FITC-labeled	NULL
Annexin	NULL
V	NULL
and	NULL
PI	NULL
and	NULL
analyzed	NULL
on	NULL
the	NULL
FACS	NULL
.	NULL

©	NULL
Apoptotic	NULL
cells	NULL
are	NULL
Annexin	NULL
V-positive	NULL
and	NULL
Pl-negative	NULL
.	NULL

``	NULL
Necrotic	NULL
cells	NULL
are	NULL
double	NULL
positive	NULL
.	NULL

©	NULL
Sum	NULL
of	NULL
apoptotic	NULL
and	NULL
necrotic	NULL
cells	NULL
.	NULL

/	NULL
Staurosporine	NULL
was	NULL
added	NULL
at	NULL
36	NULL
h.	NULL
To	NULL
analyze	NULL
in	NULL
more	NULL
detail	NULL
the	NULL
cell	NULL
cycle	NULL
block	NULL
and	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
PNU156804	NULL
showed	NULL
the	NULL
same	NULL
mechanism	NULL
of	NULL
action	NULL
as	NULL
UP	NULL
(	NULL
5	NULL
)	NULL
,	NULL
we	NULL
further	NULL
analyzed	NULL
expression	NULL
of	NULL
some	NULL
selected	NULL
cell	NULL
cycle-regulated	NULL
genes	NULL
.	NULL

In	NULL
particular	NULL
we	NULL
investigated	NULL
the	NULL
effect	NULL
of	NULL
PNU156804	NULL
on	NULL
cyclin	NULL
D2	NULL
,	NULL
cyclin	NULL
E	NULL
,	NULL
edk2	NULL
,	NULL
and	NULL
edk4	NULL
mRNA	NULL
induction	NULL
.	NULL

Like	NULL
UP	NULL
,	NULL
PNU156804	NULL
inhibited	NULL
cyclin	NULL
E	NULL
,	NULL
edk2	NULL
,	NULL
and	NULL
edk4	NULL
L	NULL
2	NULL
%	NULL
©	NULL
a	NULL
5	NULL
3	NULL
T=	NULL
0h	NULL
0	NULL
QO	NULL
fis	NULL
10	NULL
40	NULL
roo	NULL
leo	NULL
ide	NULL
tes	NULL
158	NULL
2ze	NULL
PHA	NULL
PHA	NULL
+PNU	NULL
156804	NULL
T=48	NULL
h	NULL
Cell	NULL
number	NULL
S/G2/M	NULL
24	NULL
%	NULL
S/Gz/M	NULL
6	NULL
%	NULL
16	NULL
46	NULL
rs	NULL
ree	NULL
ide	NULL
tse	NULL
158	NULL
cre	NULL
16	NULL
«	NULL
6	NULL
re	NULL
tke	NULL
tse	NULL
16o	NULL
190	NULL
eze	NULL
Channel	NULL
number	NULL
Channel	NULL
number	NULL
FIGURE	NULL
3	NULL
.	NULL

PNU156804	NULL
blocks	NULL
entry	NULL
of	NULL
T	NULL
cells	NULL
in	NULL
S	NULL
phase	NULL
.	NULL

Human	NULL
primary	NULL
T	NULL
lymphocytes	NULL
were	NULL
stimulated	NULL
with	NULL
PHA	NULL
alone	NULL
or	NULL
in	NULL
presence	NULL
of	NULL
300	NULL
ng/ml	NULL
PNU156804	NULL
.	NULL

Cells	NULL
were	NULL
collected	NULL
at	NULL
the	NULL
indicated	NULL
times	NULL
and	NULL
analyzed	NULL
for	NULL
cell	NULL
cycle	NULL
after	NULL
PI	NULL
staining	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
7105	NULL
A	NULL
0	NULL
24	NULL
48	NULL
hours	NULL
B	NULL
0	NULL
24	NULL
48	NULL
hours	NULL
-o	NULL
+	NULL
+o	NULL
+o	NULL
+0	NULL
PHA	NULL
CO	NULL
£0	NULL
+o	NULL
+0	NULL
+	NULL
PHA	NULL
kb	NULL
oo	NULL
~	NULL
o	NULL
~	NULL
t	NULL
+	NULL
-	NULL
PNU	NULL
156804	NULL
kD	NULL
>	NULL
o	NULL
>	NULL
0	NULL
o-	NULL
+-	NULL
156804	NULL
FIGURE	NULL
4	NULL
.	NULL

Pattern	NULL
of	NULL
cell	NULL
cycle	NULL
genes	NULL
inhibited	NULL
6	NULL
-	NULL
«	NULL
.	NULL

wun	NULL
<	NULL
cyclin	NULL
D2	NULL
33	NULL
-	NULL
@	NULL
-	NULL
<	NULL
by	NULL
PNU156804	NULL
.	NULL

Human	NULL
T	NULL
lymphocytes	NULL
were	NULL
stimulated	NULL
with	NULL
PHA	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
300	NULL
ng/ml	NULL
PNU156804	NULL
.	NULL

At	NULL
the	NULL
indicated	NULL
times	NULL
,	NULL
either	NULL
2.5	NULL
-	NULL
tue	NULL
<	NULL
4	NULL
cyclin	NULL
E	NULL
54	NULL
-	NULL
(	NULL
@	NULL
ee	NULL
-	NULL
ND	NULL
-	NULL
fm®	NULL
«	NULL
€	NULL
RNA	NULL
or	NULL
proteins	NULL
were	NULL
extracted	NULL
and	NULL
analyzed	NULL
by	NULL
Northern	NULL
blot	NULL
(	NULL
A4	NULL
)	NULL
or	NULL
Western	NULL
blot	NULL
(	NULL
B	NULL
)	NULL
,	NULL
using	NULL
the	NULL
in-	NULL
112414	NULL
j	NULL
dicated	NULL
probes	NULL
or	NULL
Abs	NULL
,	NULL
respectively	NULL
.	NULL

ND	NULL
,	NULL
not	NULL
done	NULL
.	NULL

2.6	NULL
-	NULL
we	NULL
te	NULL
«	NULL
€	NULL
cdk2	NULL
110	NULL
[	NULL
a	NULL
L	NULL
--	NULL
<	NULL
{	NULL
Rb	NULL
1.8	NULL
-	NULL
€	NULL
cdk4	NULL
27	NULL
-	NULL
|	NULL
eee	NULL
<	NULL
€p27	NULL
expression	NULL
but	NULL
not	NULL
cyclin	NULL
D2	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
.	NULL

Inhibition	NULL
of	NULL
edk2	NULL
,	NULL
edk4	NULL
,	NULL
and	NULL
cyclin	NULL
E	NULL
was	NULL
confirmed	NULL
at	NULL
the	NULL
protein	NULL
level	NULL
in	NULL
Western	NULL
blots	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
demonstrated	NULL
that	NULL
,	NULL
similarly	NULL
to	NULL
UP	NULL
,	NULL
PNU156804	NULL
inhibited	NULL
the	NULL
hyperphosphorylation	NULL
of	NULL
retinoblastoma	NULL
protein	NULL
(	NULL
Rb	NULL
)	NULL
,	NULL
observable	NULL
as	NULL
a	NULL
series	NULL
of	NULL
bands	NULL
of	NULL
higher	NULL
apparent	NULL
m.w	NULL
.	NULL

(	NULL
p112-114	NULL
)	NULL
in	NULL
Western	NULL
blots	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
PNU156804	NULL
,	NULL
like	NULL
UP	NULL
,	NULL
did	NULL
not	NULL
inhibit	NULL
the	NULL
down-regulation	NULL
of	NULL
p27	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

All	NULL
together	NULL
,	NULL
the	NULL
data	NULL
presented	NULL
demonstrate	NULL
that	NULL
PNU156804	NULL
efficiently	NULL
inhibits	NULL
human	NULL
T	NULL
cell	NULL
proliferation	NULL
with	NULL
little	NULL
toxicity	NULL
,	NULL
that	NULL
it	NULL
blocks	NULL
T	NULL
cells	NULL
in	NULL
mid-late	NULL
G	NULL
,	NULL
,	NULL
and	NULL
that	NULL
it	NULL
shows	NULL
a	NULL
similar	NULL
mechanism	NULL
of	NULL
action	NULL
as	NULL
UP	NULL
at	NULL
least	NULL
as	NULL
far	NULL
as	NULL
cell	NULL
cycle	NULL
genes	NULL
are	NULL
concerned	NULL
.	NULL

PNU156804	NULL
blocks	NULL
IL-2-dependent	NULL
T	NULL
cell	NULL
proliferation	NULL
G	NULL
,	NULL
-G	NULL
,	NULL
phase	NULL
progression	NULL
in	NULL
T	NULL
cells	NULL
is	NULL
accompanied	NULL
by	NULL
induction	NULL
of	NULL
IL-2	NULL
and	NULL
the	NULL
IL-2R	NULL
,	NULL
and	NULL
signaling	NULL
by	NULL
IL-2	NULL
drives	NULL
entry	NULL
into	NULL
S	NULL
phase	NULL
(	NULL
8	NULL
,	NULL
9	NULL
)	NULL
.	NULL

In	NULL
these	NULL
cells	NULL
,	NULL
the	NULL
IL-2R	NULL
is	NULL
mostly	NULL
regulated	NULL
by	NULL
induction	NULL
of	NULL
the	NULL
-chain	NULL
during	NULL
activation	NULL
,	NULL
allowing	NULL
high	NULL
affinity	NULL
binding	NULL
(	NULL
9	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
investigated	NULL
the	NULL
effect	NULL
of	NULL
PNU156804	NULL
on	NULL
IL-2	NULL
and	NULL
IL-2R	NULL
a-chain	NULL
expression	NULL
.	NULL

IL-2Ra	NULL
mRNA	NULL
was	NULL
strongly	NULL
induced	NULL
by	NULL
PHA	NULL
and	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
PNU156804	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

At	NULL
the	NULL
protein	NULL
level	NULL
,	NULL
induction	NULL
of	NULL
IL-2Ra	NULL
by	NULL
PHA	NULL
was	NULL
slightly	NULL
lower	NULL
but	NULL
was	NULL
not	NULL
abolished	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PNU156804	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

IL-2	NULL
expression	NULL
was	NULL
not	NULL
affected	NULL
at	NULL
either	NULL
the	NULL
protein	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
or	NULL
RNA	NULL
level	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
as	NULL
previously	NULL
observed	NULL
for	NULL
UP	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Since	NULL
expression	NULL
of	NULL
the	NULL
IL-2R	NULL
y-chain	NULL
also	NULL
increases	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
(	NULL
9	NULL
)	NULL
,	NULL
we	NULL
also	NULL
investigated	NULL
its	NULL
regulation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
drug	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
y-chain	NULL
mRNA	NULL
induction	NULL
was	NULL
unaffected	NULL
by	NULL
PNU156804	NULL
.	NULL

All	NULL
together	NULL
,	NULL
these	NULL
data	NULL
suggest	NULL
that	NULL
PNU156804	NULL
0	NULL
24	NULL
48	NULL
_	NULL
hours	NULL
-o	NULL
o	NULL
$	NULL
o	NULL
$	NULL
4	NULL
+	NULL
PHA	NULL
-o	NULL
-	NULL
o	NULL
o-	NULL
+-	NULL
PNU	NULL
156804	NULL
3.5	NULL
kb	NULL
-	NULL
as	NULL
a	NULL
b	NULL
a	NULL
W	NULL
<	NULL
20kb-	NULL
-	NULL
®	NULL
M	NULL
M	NULL
u	NULL
<	NULL
€IL-2Ry	NULL
_	NULL
|	NULL
-285	NULL
``	NULL
|	NULL
-18s	NULL
FIGURE	NULL
5	NULL
.	NULL

Induction	NULL
of	NULL
IL-2Ra	NULL
and	NULL
y	NULL
mRNA	NULL
is	NULL
not	NULL
blocked	NULL
by	NULL
PNU156804	NULL
.	NULL

Human	NULL
T	NULL
lymphocytes	NULL
were	NULL
stimulated	NULL
with	NULL
PHA	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
300	NULL
ng/ml	NULL
PNU156804	NULL
.	NULL

RNA	NULL
extracted	NULL
at	NULL
the	NULL
indicated	NULL
times	NULL
was	NULL
analyzed	NULL
for	NULL
IL-2Ra	NULL
«	NULL
and	NULL
y	NULL
expression	NULL
by	NULL
Northern	NULL
blot	NULL
.	NULL

inhibits	NULL
T	NULL
cell	NULL
proliferation	NULL
mostly	NULL
downstream	NULL
from	NULL
IL-2	NULL
and	NULL
IL-2R	NULL
expression	NULL
,	NULL
in	NULL
agreement	NULL
with	NULL
a	NULL
block	NULL
in	NULL
mid-late	NULL
G	NULL
,	NULL
.	NULL

To	NULL
test	NULL
directly	NULL
whether	NULL
PNU156804	NULL
inhibits	NULL
IL-2-dependent	NULL
T	NULL
cell	NULL
proliferation	NULL
,	NULL
peripheral	NULL
T	NULL
lymphocytes	NULL
were	NULL
preactivated	NULL
with	NULL
PHA	NULL
for	NULL
72	NULL
h	NULL
to	NULL
induce	NULL
IL-2R	NULL
expression	NULL
(	NULL
10	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
washed	NULL
and	NULL
starved	NULL
for	NULL
24	NULL
h	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-2	NULL
.	NULL

rhIL-2	NULL
was	NULL
then	NULL
added	NULL
to	NULL
the	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
PNU156804	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
preactivated	NULL
starved	NULL
T	NULL
cells	NULL
required	NULL
exog-enously	NULL
added	NULL
IL-2	NULL
to	NULL
proliferate	NULL
,	NULL
and	NULL
this	NULL
proliferation	NULL
was	NULL
inhibited	NULL
efficiently	NULL
by	NULL
PNU156804	NULL
.	NULL

Furthermore	NULL
the	NULL
dose-response	NULL
curve	NULL
for	NULL
inhibition	NULL
of	NULL
IL-2-dependent	NULL
proliferation	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
was	NULL
superimposable	NULL
to	NULL
that	NULL
obtained	NULL
on	NULL
primary	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
PNU156804	NULL
inhibits	NULL
events	NULL
taking	NULL
place	NULL
downstream	NULL
from	NULL
the	NULL
interaction	NULL
of	NULL
IL-2	NULL
with	NULL
its	NULL
receptor	NULL
.	NULL

PNU156804	NULL
specifically	NULL
inhibits	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
AP-1	NULL
Several	NULL
signaling	NULL
cascades	NULL
are	NULL
known	NULL
to	NULL
be	NULL
triggered	NULL
by	NULL
IL-2	NULL
that	NULL
lead	NULL
to	NULL
the	NULL
expression	NULL
of	NULL
different	NULL
sets	NULL
of	NULL
genes	NULL
and	NULL
transcription	NULL
factors	NULL
thought	NULL
to	NULL
be	NULL
important	NULL
for	NULL
the	NULL
proliferative	NULL
and	NULL
antiapoptotic	NULL
response	NULL
of	NULL
T	NULL
cells	NULL
(	NULL
8	NULL
,	NULL
9	NULL
,	NULL
11-13	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
in	NULL
more	NULL
detail	NULL
the	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
PNU156804	NULL
and	NULL
determine	NULL
which	NULL
signaling	NULL
pathway	NULL
is	NULL
affected	NULL
by	NULL
the	NULL
drug	NULL
,	NULL
we	NULL
have	NULL
set	NULL
out	NULL
to	NULL
determine	NULL
the	NULL
effect	NULL
of	NULL
PNU156804	NULL
on	NULL
the	NULL
pathways	NULL
triggered	NULL
by	NULL
IL-2	NULL
,	NULL
which	NULL
are	NULL
thought	NULL
to	NULL
be	NULL
important	NULL
for	NULL
the	NULL
proliferative	NULL
response	NULL
of	NULL
the	NULL
cells	NULL
,	NULL
in	NULL
particular	NULL
the	NULL
induction	NULL
of	NULL
c-myc	NULL
,	NULL
bel-2	NULL
,	NULL
AP-1	NULL
,	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
using	NULL
the	NULL
IL-2-dependent	NULL
system	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

74	NULL
,	NULL
c-mye	NULL
mRNA	NULL
is	NULL
strongly	NULL
induced	NULL
at	NULL
3	NULL
h	NULL
after	NULL
addition	NULL
of	NULL
IL-2	NULL
,	NULL
and	NULL
this	NULL
induction	NULL
is	NULL
not	NULL
affected	NULL
by	NULL
PNU156804	NULL
.	NULL

Similarly	NULL
,	NULL
bel-2	NULL
expression	NULL
is	NULL
clearly	NULL
up-regulated	NULL
with	NULL
a	NULL
peak	NULL
around	NULL
8-12	NULL
h	NULL
after	NULL
stimulation	NULL
with	NULL
IL-2	NULL
,	NULL
and	NULL
this	NULL
stimulation	NULL
is	NULL
not	NULL
inhibited	NULL
by	NULL
PNU156804	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
PNU156804	NULL
does	NULL
not	NULL
affect	NULL
the	NULL
signaling	NULL
pathways	NULL
that	NULL
lead	NULL
to	NULL
c-myc	NULL
and	NULL
bel-2	NULL
induction	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
.	NULL

Table	NULL
II	NULL
.	NULL

Effect	NULL
of	NULL
PNU156804	NULL
on	NULL
the	NULL
induction	NULL
of	NULL
IL-2	NULL
and	NULL
IL-2Ra	NULL
proteins	NULL
IL-2	NULL
``	NULL
,	NULL
ng/ml	NULL
IL-2Ra	NULL
``	NULL
,	NULL
%	NULL
Treatment	NULL
(	NULL
SD	NULL
)	NULL
Positive	NULL
(	NULL
MF	NULL
]	NULL
)	NULL
T	NULL
=	NULL
0	NULL
0.03	NULL
(	NULL
0.001	NULL
)	NULL
5.9	NULL
PHA	NULL
24	NULL
h	NULL
0.41	NULL
(	NULL
0.076	NULL
)	NULL
47.4	NULL
(	NULL
457	NULL
)	NULL
PHA	NULL
24	NULL
h	NULL
+	NULL
PNU156804°	NULL
0.53	NULL
(	NULL
0.015	NULL
)	NULL
29.3	NULL
(	NULL
389	NULL
)	NULL
``	NULL
IL-2	NULL
protein	NULL
secreted	NULL
was	NULL
measured	NULL
by	NULL
ELISA	NULL
.	NULL

*	NULL
Surface	NULL
expression	NULL
was	NULL
measured	NULL
by	NULL
FACS	NULL
analysis	NULL
.	NULL

MFI	NULL
,	NULL
mean	NULL
fluorescence	NULL
intensity	NULL
.	NULL

©	NULL
PUN156804	NULL
was	NULL
added	NULL
at	NULL
300	NULL
ng/ml	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
7106	NULL
60	NULL
-o-	NULL
-	NULL
IL-2	NULL
g	NULL
-B-	NULL
+	NULL
IL-2	NULL
A	NULL
g	NULL
597	NULL
-A-	NULL
+	NULL
IL-2	NULL
+	NULL
PNU	NULL
156804	NULL
'	NULL
o	NULL
®	NULL
405	NULL
0	NULL
S	NULL
§	NULL
so-a	NULL
3	NULL
o	NULL
/E|	NULL
£	NULL
207	NULL
L	NULL
§	NULL
``	NULL
|	NULL
¢	NULL
€	NULL
E	NULL
10	NULL
7	NULL
E-I	NULL
0	NULL
+	NULL
--	NULL
-	NULL
r	NULL
t	NULL
24	NULL
48	NULL
72	NULL
Time	NULL
(	NULL
hours	NULL
)	NULL
120	NULL
100	NULL
7	NULL
80	NULL
7	NULL
60	NULL
7	NULL
40	NULL
{	NULL
20	NULL
7	NULL
Thymidine	NULL
uptake	NULL
(	NULL
x10°	NULL
cpm	NULL
)	NULL
0	NULL
I	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
0	NULL
200	NULL
400	NULL
600	NULL
800	NULL
PNU	NULL
156804	NULL
(	NULL
ng/m	NULL
!	NULL
)	NULL

FIGURE	NULL
6	NULL
.	NULL

PNU156804	NULL
inhibits	NULL
IL-2-dependent	NULL
T	NULL
cell	NULL
proliferation	NULL
.	NULL

Human	NULL
T	NULL
cells	NULL
preactivated	NULL
with	NULL
PHA	NULL
for	NULL
72	NULL
h	NULL
were	NULL
starved	NULL
for	NULL
24	NULL
h	NULL
in	NULL
1	NULL
%	NULL
FCS	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-2	NULL
.	NULL

They	NULL
were	NULL
then	NULL
stimulated	NULL
with	NULL
200	NULL
U/ml	NULL
rhIL-2	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
PNU156804	NULL
at	NULL
300	NULL
ng/ml	NULL
(	NULL
4	NULL
)	NULL
or	NULL
different	NULL
doses	NULL
(	NULL
B	NULL
)	NULL
.	NULL

[	NULL
°H	NULL
]	NULL
Thymidine	NULL
incorporation	NULL
was	NULL
measured	NULL
at	NULL
the	NULL
indicated	NULL
times	NULL
(	NULL
4	NULL
)	NULL
or	NULL
at	NULL
48	NULL
h	NULL
(	NULL
B	NULL
)	NULL
.	NULL

We	NULL
next	NULL
set	NULL
out	NULL
to	NULL
measure	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
transcription	NULL
factors	NULL
AP-1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

For	NULL
this	NULL
purpose	NULL
,	NULL
an	NULL
EMSA	NULL
was	NULL
chosen	NULL
that	NULL
can	NULL
directly	NULL
measure	NULL
the	NULL
activation	NULL
state	NULL
of	NULL
these	NULL
factors	NULL
in	NULL
nuclear	NULL
extracts	NULL
.	NULL

Oligonucleotides	NULL
carrying	NULL
a	NULL
binding	NULL
site	NULL
specific	NULL
for	NULL
each	NULL
transcription	NULL
factor	NULL
were	NULL
used	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

84	NULL
,	NULL
both	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
AP-1	NULL
,	NULL
which	NULL
are	NULL
also	NULL
strongly	NULL
induced	NULL
4	NULL
h	NULL
after	NULL
addition	NULL
of	NULL
IL-2	NULL
,	NULL
were	NULL
inhibited	NULL
by	NULL
up	NULL
to	NULL
90	NULL
%	NULL
by	NULL
PNU156804	NULL
.	NULL

Competition	NULL
assays	NULL
with	NULL
the	NULL
cold	NULL
AP-1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
oligonucleotides	NULL
confirmed	NULL
that	NULL
the	NULL
retarded	NULL
bands	NULL
were	NULL
specific	NULL
(	NULL
Fig	NULL
.	NULL

8A	NULL
)	NULL
.	NULL

A	NULL
B	NULL
0	NULL
3	NULL
hours	NULL
0	NULL
8	NULL
hours	NULL
-o	NULL
-	NULL
+	NULL
o+	NULL
IL-2	NULL
C2	NULL
2	NULL
o£	NULL
+	NULL
IL-2	NULL
-	NULL
o=	NULL
=	NULL
+	NULL
PNU	NULL
156804	NULL
-	NULL
=	NULL
=	NULL
+	NULL
PNU	NULL
156804	NULL
2.4	NULL
kb	NULL
-	NULL
mH	NULL
<	NULL
omye	NULL
_	NULL
WD	NULL
W	NULL
<	NULL
bci-2	NULL
FIGURE	NULL
7	NULL
.	NULL

PNU156804	NULL
does	NULL
not	NULL
inhibit	NULL
the	NULL
IL-2-induced	NULL
expression	NULL
of	NULL
c-myc	NULL
and	NULL
bel-2	NULL
.	NULL

Preactivated	NULL
primary	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
rhIL-2	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
300	NULL
ng/ml	NULL
PNU156804	NULL
.	NULL

RNA	NULL
was	NULL
extracted	NULL
at	NULL
0	NULL
,	NULL
3	NULL
,	NULL
or	NULL
8	NULL
h	NULL
following	NULL
stimulation	NULL
and	NULL
analyzed	NULL
for	NULL
c-myc	NULL
(	NULL
A	NULL
)	NULL
or	NULL
bel-2	NULL
(	NULL
B	NULL
)	NULL
expression	NULL
by	NULL
Northern	NULL
blotting	NULL
.	NULL

INHIBITION	NULL
OF	NULL
IL-2-DEPENDENT	NULL
SIGNALING	NULL
BY	NULL
PNU156804	NULL
NE-	NULL
«	NULL
B	NULL
and	NULL
AP-1	NULL
are	NULL
known	NULL
to	NULL
be	NULL
activated	NULL
by	NULL
many	NULL
extracellular	NULL
signals	NULL
and	NULL
several	NULL
second	NULL
messenger	NULL
cascades	NULL
(	NULL
9	NULL
,	NULL
13-15	NULL
)	NULL
.	NULL

Since	NULL
PNU156804	NULL
blocks	NULL
IL-2-driven	NULL
G	NULL
,	NULL
-S	NULL
proliferation	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
PNU156804	NULL
could	NULL
also	NULL
inhibit	NULL
PMA-induced	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
AP-1	NULL
in	NULL
resting	NULL
T	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

8B	NULL
,	NULL
PMA	NULL
strongly	NULL
activated	NULL
both	NULL
transcription	NULL
factors	NULL
,	NULL
but	NULL
PNU156804	NULL
did	NULL
not	NULL
inhibit	NULL
this	NULL
activation	NULL
in	NULL
any	NULL
way	NULL
.	NULL

Similarly	NULL
,	NULL
PNU156804	NULL
showed	NULL
no	NULL
inhibitory	NULL
effect	NULL
on	NULL
PHA-induced	NULL
AP-1	NULL
or	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
PNU156804	NULL
specifically	NULL
inhibits	NULL
IL-2-	NULL
and	NULL
not	NULL
phorbol	NULL
ester-	NULL
or	NULL
PHA-triggered	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
AP-1	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

To	NULL
evaluate	NULL
the	NULL
specificity	NULL
of	NULL
inhibition	NULL
by	NULL
PNU156804	NULL
for	NULL
IL-2	NULL
signaling	NULL
,	NULL
we	NULL
also	NULL
investigated	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
drug	NULL
on	NULL
a	NULL
more	NULL
physiological	NULL
signal	NULL
such	NULL
as	NULL
CD40	NULL
triggering	NULL
of	NULL
a	NULL
B	NULL
cell	NULL
line	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

8C	NULL
,	NULL
the	NULL
results	NULL
show	NULL
that	NULL
PNU156804	NULL
can	NULL
inhibit	NULL
CDA4O-triggered	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
measured	NULL
by	NULL
EMSA	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
PNU156804	NULL
blocks	NULL
NF-KB	NULL
induction	NULL
by	NULL
some	NULL
(	NULL
IL-2	NULL
,	NULL
CD40	NULL
)	NULL
but	NULL
not	NULL
all	NULL
(	NULL
PMA	NULL
,	NULL
PHA	NULL
)	NULL
signals	NULL
.	NULL

PNU156804	NULL
inhibits	NULL
NF-KB	NULL
activation	NULL
through	NULL
inhibition	NULL
of	NULL
IxB	NULL
degradation	NULL
To	NULL
investigate	NULL
in	NULL
more	NULL
detail	NULL
by	NULL
which	NULL
mechanism	NULL
PNU156804	NULL
inhibited	NULL
NF-KB	NULL
activation	NULL
,	NULL
we	NULL
first	NULL
conducted	NULL
supershift	NULL
experiments	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

94	NULL
,	NULL
anti-p50	NULL
Abs	NULL
supershifted	NULL
completely	NULL
the	NULL
IL-2-induced	NULL
NF-	NULL
«	NULL
B	NULL
complex	NULL
,	NULL
whereas	NULL
anti-p65	NULL
Abs	NULL
led	NULL
only	NULL
to	NULL
a	NULL
partial	NULL
supershift	NULL
.	NULL

This	NULL
indicates	NULL
that	NULL
the	NULL
IL-2-induced	NULL
NF-	NULL
«	NULL
B	NULL
complexes	NULL
contain	NULL
p50/p65	NULL
heterodimers	NULL
as	NULL
well	NULL
as	NULL
p50	NULL
ho-modimers	NULL
or	NULL
p50	NULL
complexed	NULL
with	NULL
another	NULL
c-re/	NULL
family	NULL
member	NULL
.	NULL

NE-	NULL
«	NULL
B	NULL
activation	NULL
is	NULL
usually	NULL
regulated	NULL
through	NULL
phosphorylation	NULL
of	NULL
IB	NULL
,	NULL
the	NULL
NF-	NULL
«	NULL
B-associated	NULL
inhibitor	NULL
,	NULL
with	NULL
degradation	NULL
of	NULL
IB	NULL
followed	NULL
by	NULL
translocation	NULL
of	NULL
free	NULL
NF-KB	NULL
to	NULL
the	NULL
nucleus	NULL
(	NULL
15	NULL
,	NULL
16	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
investigated	NULL
the	NULL
effect	NULL
of	NULL
PNU156804	NULL
on	NULL
cytoplasmic	NULL
IkB-a	NULL
and	NULL
IxB-B	NULL
expression	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

9B	NULL
,	NULL
IL-2	NULL
induced	NULL
a	NULL
rapid	NULL
degradation	NULL
of	NULL
and	NULL
IxB-f3	NULL
,	NULL
and	NULL
this	NULL
degradation	NULL
was	NULL
completely	NULL
blocked	NULL
by	NULL
PNU156804	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
PNU156804	NULL
inhibits	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
through	NULL
inhibition	NULL
of	NULL
IB	NULL
degradation	NULL
.	NULL

Discussion	NULL
In	NULL
this	NULL
report	NULL
,	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
new	NULL
analogue	NULL
of	NULL
the	NULL
prodigiosin	NULL
family	NULL
of	NULL
immunosuppressive	NULL
drugs	NULL
(	NULL
5	NULL
,	NULL
17	NULL
,	NULL
18	NULL
)	NULL
,	NULL
PNU156804	NULL
,	NULL
is	NULL
described	NULL
for	NULL
the	NULL
first	NULL
time	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
PNU156804	NULL
on	NULL
human	NULL
primary	NULL
T	NULL
lymphocytes	NULL
is	NULL
investigated	NULL
in	NULL
detail	NULL
.	NULL

The	NULL
major	NULL
conclusions	NULL
that	NULL
can	NULL
be	NULL
drawn	NULL
are	NULL
the	NULL
following	NULL
.	NULL

1	NULL
)	NULL
PNU156804	NULL
efficiently	NULL
inhibits	NULL
the	NULL
proliferation	NULL
of	NULL
primary	NULL
human	NULL
T	NULL
and	NULL
B	NULL
lymphocytes	NULL
triggered	NULL
by	NULL
mitogenic	NULL
or	NULL
antigenic	NULL
stimuli	NULL
(	NULL
MLR	NULL
)	NULL
.	NULL

2	NULL
)	NULL
The	NULL
proliferation	NULL
block	NULL
takes	NULL
place	NULL
in	NULL
mid	NULL
to	NULL
late	NULL
G	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
cell	NULL
cycle	NULL
analysis	NULL
and	NULL
the	NULL
pattern	NULL
of	NULL
expression	NULL
of	NULL
cell	NULL
cycle	NULL
genes	NULL
.	NULL

3	NULL
)	NULL
PNU156804	NULL
inhibits	NULL
T	NULL
cell	NULL
proliferation	NULL
downstream	NULL
from	NULL
the	NULL
induction	NULL
of	NULL
IL-2	NULL
and	NULL
the	NULL
IL-2R	NULL
and	NULL
indeed	NULL
blocks	NULL
IL-2-dependent	NULL
T	NULL
cell	NULL
proliferation	NULL
.	NULL

4	NULL
)	NULL
PNU156804	NULL
does	NULL
not	NULL
inhibit	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
c-myc	NULL
and	NULL
bel-2	NULL
genes	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
.	NULL

5	NULL
)	NULL
PNU156804	NULL
efficiently	NULL
blocks	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
AP-1	NULL
transcription	NULL
factors	NULL
induced	NULL
by	NULL
IL-2	NULL
.	NULL

It	NULL
has	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
same	NULL
factors	NULL
triggered	NULL
by	NULL
phorbol	NULL
ester	NULL
or	NULL
PHA	NULL
.	NULL

However	NULL
,	NULL
it	NULL
blocks	NULL
NF-KB	NULL
activation	NULL
by	NULL
CD40	NULL
on	NULL
B	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
PNU156804	NULL
target	NULL
is	NULL
not	NULL
restricted	NULL
to	NULL
IL-2	NULL
signaling	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
PNU156804	NULL
targets	NULL
a	NULL
signaling	NULL
pathway	NULL
triggered	NULL
by	NULL
IL-2	NULL
that	NULL
leads	NULL
to	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
AP-1	NULL
.	NULL

Furthermore	NULL
we	NULL
hypothesize	NULL
that	NULL
the	NULL
effect	NULL
of	NULL
PNU156804	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
AP-1	NULL
activation	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
block	NULL
of	NULL
T	NULL
cell	NULL
proliferation	NULL
brought	NULL
about	NULL
by	NULL
the	NULL
drug	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
data	NULL
presented	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
A	NULL
B	NULL
IL-2	NULL
«	NULL
oles	NULL
Brage	NULL
croc	NULL
fe	NULL
PNU	NULL
156804	NULL
PNU156804	NULL
.	NULL

non	NULL
e	NULL
pe	NULL
e	NULL
>	NULL
#	NULL
PVA	NULL
Cold	NULL
competitor	NULL
-	NULL
-	NULL
4	NULL
-	NULL
-	NULL
-	NULL
+	NULL
B	NULL
-	NULL
g	NULL
#	NULL
-B	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
NF-	NULL
«	NULL
B	NULL
AP-1	NULL
F—u	NULL
7107	NULL
C	NULL
weg	NULL
-	NULL
gre	NULL
x~	NULL
<	NULL
p	NULL
PNU	NULL
156804	NULL
-	NULL
-	NULL
+	NULL
-o	NULL
+	NULL
o+	NULL
-o	NULL
+o	NULL
CD40	NULL
-	NULL
o£	NULL
+	NULL
B	NULL
-	NULL
«	NULL
ame	NULL
-B	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
1	NULL
2	NULL
3	NULL
NF-	NULL
«	NULL
B	NULL
AP-1	NULL
NF-	NULL
«	NULL
B	NULL
FIGURE	NULL
8	NULL
.	NULL

PNU156804	NULL
inhibits	NULL
IL-2	NULL
but	NULL
not	NULL
PMA-induced	NULL
NF-KB	NULL
and	NULL
AP-1	NULL
activation	NULL
.	NULL

A	NULL
,	NULL
PHA-preactivated	NULL
human	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
200	NULL
U/ml	NULL
rhIL-2	NULL
.	NULL

PNU156804	NULL
was	NULL
added	NULL
10	NULL
min	NULL
before	NULL
IL-2	NULL
.	NULL

B	NULL
,	NULL
Resting	NULL
human	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
20	NULL
ng/ml	NULL
PMA	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
4	NULL
h	NULL
after	NULL
addition	NULL
of	NULL
the	NULL
stimulus	NULL
and	NULL
used	NULL
in	NULL
EMSA	NULL
using	NULL
the	NULL
indicated	NULL
probes	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
a	NULL
250-fold	NULL
molar	NULL
excess	NULL
of	NULL
cold	NULL
specific	NULL
oligonu-cleotide	NULL
was	NULL
added	NULL
(	NULL
cold	NULL
competitor	NULL
)	NULL
.	NULL

C	NULL
,	NULL
BJAB	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
anti-CD40	NULL
Ab	NULL
(	NULL
1	NULL
ug/ml	NULL
!	NULL
)	NULL

and	NULL
PNU156804	NULL
(	NULL
300	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
4	NULL
h.	NULL
Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
and	NULL
tested	NULL
in	NULL
EMSA	NULL
with	NULL
the	NULL
NF-KB	NULL
probe	NULL
.	NULL

demonstrate	NULL
that	NULL
PNU156804	NULL
shows	NULL
a	NULL
different	NULL
mechanism	NULL
of	NULL
action	NULL
than	NULL
other	NULL
immunosuppressive	NULL
drugs	NULL
such	NULL
as	NULL
CsA	NULL
,	NULL
FK506	NULL
,	NULL
and	NULL
rapamycin	NULL
(	NULL
3	NULL
,	NULL
19-21	NULL
)	NULL
.	NULL

The	NULL
effectiveness	NULL
of	NULL
PNU156804	NULL
action	NULL
,	NULL
its	NULL
specificity	NULL
for	NULL
defined	NULL
signaling	NULL
pathways	NULL
,	NULL
and	NULL
its	NULL
diversity	NULL
from	NULL
other	NULL
immunosuppressants	NULL
,	NULL
in	NULL
particular	NULL
CsA	NULL
and	NULL
FK506	NULL
,	NULL
make	NULL
this	NULL
drug	NULL
and	NULL
other	NULL
members	NULL
of	NULL
the	NULL
prodigiosin	NULL
family	NULL
good	NULL
candidate	NULL
drugs	NULL
for	NULL
combined	NULL
immunotherapy	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
PNU156804	NULL
defined	NULL
here	NULL
makes	NULL
this	NULL
family	NULL
of	NULL
compounds	NULL
interesting	NULL
new	NULL
tools	NULL
to	NULL
dissect	NULL
the	NULL
IL-2-signal-ing	NULL
pathways	NULL
that	NULL
lead	NULL
to	NULL
T	NULL
cell	NULL
proliferation	NULL
.	NULL

A	NULL
simplified	NULL
scheme	NULL
of	NULL
the	NULL
intracellular	NULL
signaling	NULL
cascades	NULL
induced	NULL
by	NULL
IL-2	NULL
and	NULL
based	NULL
on	NULL
this	NULL
report	NULL
and	NULL
available	NULL
published	NULL
data	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

10	NULL
(	NULL
8	NULL
,	NULL
9	NULL
,	NULL
12	NULL
,	NULL
14	NULL
,	NULL
22	NULL
,	NULL
23	NULL
)	NULL
.	NULL

The	NULL
differences	NULL
in	NULL
the	NULL
effects	NULL
of	NULL
PNU156804	NULL
and	NULL
rapamycin	NULL
on	NULL
these	NULL
cascades	NULL
are	NULL
also	NULL
indicated	NULL
.	NULL

Previously	NULL
we	NULL
had	NULL
investigated	NULL
the	NULL
biological	NULL
effects	NULL
of	NULL
the	NULL
first	NULL
isolated	NULL
member	NULL
of	NULL
the	NULL
prodigiosin	NULL
family	NULL
,	NULL
UP	NULL
,	NULL
on	NULL
human	NULL
T	NULL
and	NULL
B	NULL
lymphocytes	NULL
in	NULL
vitro	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Although	NULL
UP	NULL
showed	NULL
a	NULL
strong	NULL
inhibitory	NULL
A	NULL
+	NULL
IL-2	NULL
B	NULL
m-	NULL
>	NULL
o	NULL
ip	NULL
G	NULL
ip	NULL
©	NULL
0	NULL
a	NULL
a	NULL
8B	NULL
#	NULL
‘	NULL
g	NULL
5	NULL
5	NULL
-	NULL
+	NULL
+00	NULL
IL-2	NULL
60+	NULL
+	NULL
kD	NULL
-	NULL
+	NULL
PNU	NULL
156804	NULL
=s	NULL
37	NULL
<	NULL
-IxB-a	NULL
®	NULL
-B	NULL
43	NULL
<	NULL
-IxB-B	NULL
1	NULL
2	NULL
3	NULL
hm	NULL
1	NULL
2	NULL
3	NULL
FIGURE	NULL
9	NULL
.	NULL

PNU156804	NULL
inhibits	NULL
the	NULL
IL-2-induced	NULL
down-regulation	NULL
of	NULL
IkB-a	NULL
and	NULL
I	NULL
«	NULL
B-f.	NULL
Preactivated	NULL
T	NULL
lymphocytes	NULL
were	NULL
stimulated	NULL
with	NULL
rhIL-2	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
300	NULL
ng/ml	NULL
PNU156804	NULL
.	NULL

Nuclear	NULL
extracts	NULL
for	NULL
band	NULL
shift	NULL
experiments	NULL
(	NULL
A	NULL
)	NULL
or	NULL
cytoplasmic	NULL
extracts	NULL
for	NULL
Western	NULL
blots	NULL
(	NULL
B	NULL
)	NULL
were	NULL
prepared	NULL
.	NULL

IL-2-stimulated	NULL
NF-KB	NULL
activity	NULL
was	NULL
analyzed	NULL
in	NULL
EMSA	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
the	NULL
indicated	NULL
Abs	NULL
(	NULL
4	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
IxB-	NULL
«	NULL
and	NULL
IxB-B	NULL
was	NULL
analyzed	NULL
by	NULL
Western	NULL
blotting	NULL
(	NULL
B	NULL
)	NULL
.	NULL

activity	NULL
on	NULL
the	NULL
proliferation	NULL
of	NULL
primary	NULL
lymphocytes	NULL
without	NULL
affecting	NULL
significantly	NULL
the	NULL
in	NULL
vitro	NULL
growth	NULL
of	NULL
leukemic	NULL
cell	NULL
lines	NULL
,	NULL
it	NULL
showed	NULL
too	NULL
severe	NULL
toxic	NULL
side	NULL
effects	NULL
during	NULL
prolonged	NULL
in	NULL
vivo	NULL
treatment	NULL
in	NULL
mice	NULL
to	NULL
permit	NULL
its	NULL
development	NULL
as	NULL
a	NULL
therapeutic	NULL
agent	NULL
.	NULL

For	NULL
this	NULL
reason	NULL
,	NULL
a	NULL
screening	NULL
was	NULL
performed	NULL
to	NULL
identify	NULL
new	NULL
analogues	NULL
of	NULL
UP	NULL
with	NULL
more	NULL
favorable	NULL
activities	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
in	NULL
mice	NULL
,	NULL
and	NULL
PNU156804	NULL
was	NULL
identified	NULL
as	NULL
a	NULL
suitable	NULL
candidate	NULL
since	NULL
it	NULL
has	NULL
a	NULL
lower	NULL
ratio	NULL
of	NULL
toxic	NULL
vs	NULL
effective	NULL
dose	NULL
than	NULL
UP	NULL
.	NULL

The	NULL
effect	NULL
and	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
PNU156804	NULL
were	NULL
investigated	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

The	NULL
first	NULL
part	NULL
of	NULL
this	NULL
report	NULL
was	NULL
directed	NULL
at	NULL
determining	NULL
the	NULL
activity	NULL
of	NULL
PNU156804	NULL
on	NULL
human	NULL
T	NULL
and	NULL
B	NULL
lymphocytes	NULL
,	NULL
the	NULL
point	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
where	NULL
the	NULL
cells	NULL
became	NULL
blocked	NULL
,	NULL
and	NULL
at	NULL
comparing	NULL
the	NULL
activity	NULL
of	NULL
PNU156804	NULL
with	NULL
that	NULL
of	NULL
UP	NULL
itself	NULL
,	NULL
as	NULL
well	NULL
as	NULL
of	NULL
other	NULL
known	NULL
immunosuppressive	NULL
drugs	NULL
such	NULL
as	NULL
rapamycin	NULL
.	NULL

PNU156804	NULL
was	NULL
found	NULL
to	NULL
inhibit	NULL
the	NULL
proliferation	NULL
of	NULL
human	NULL
T	NULL
and	NULL
B	NULL
lymphocytes	NULL
by	NULL
80-90	NULL
%	NULL
at	NULL
200-300	NULL
ng/ml	NULL
.	NULL

Thus	NULL
,	NULL
PNU156804	NULL
is	NULL
as	NULL
effective	NULL
as	NULL
UP	NULL
but	NULL
at	NULL
doses	NULL
4-6	NULL
times	NULL
higher	NULL
.	NULL

This	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
in	NULL
vivo	NULL
data	NULL
in	NULL
mice	NULL
.	NULL

We	NULL
have	NULL
also	NULL
determined	NULL
that	NULL
PNU156804	NULL
,	NULL
like	NULL
UP	NULL
(	NULL
5	NULL
)	NULL
,	NULL
strongly	NULL
inhibits	NULL
B	NULL
cell	NULL
proliferation	NULL
STAT3	NULL
and	NULL
5	NULL
x	NULL
?	NULL

2	NULL
``	NULL
ie	NULL
rag	NULL
*	NULL
bi	NULL
4	NULL
(	NULL
_2	NULL
]	NULL
?	NULL

2	NULL
¢	NULL
MEKK-1	NULL
kinase	NULL
I	NULL
‘	NULL
t	NULL
ERK	NULL
JNK	NULL
STAM	NULL
l	NULL
Rapamycin	NULL
mars	NULL
PKB	NULL
p7OS6K	NULL
/	NULL
(	NULL
Atk	NULL
)	NULL
?	NULL

©	NULL
PNU15S6804	NULL
Rapamycin	NULL
FIGURE	NULL
10	NULL
.	NULL

-	NULL
Schematic	NULL
of	NULL
the	NULL
intracellular	NULL
cascades	NULL
triggered	NULL
by	NULL
IL-2	NULL
binding	NULL
to	NULL
its	NULL
receptor	NULL
.	NULL

The	NULL
molecular	NULL
events	NULL
that	NULL
are	NULL
inhibited	NULL
(	NULL
-	NULL
)	NULL
by	NULL
either	NULL
rapamycin	NULL
or	NULL
PNU156804	NULL
are	NULL
indicated	NULL
.	NULL

STAM	NULL
,	NULL
signal	NULL
transducing	NULL
adaptor	NULL
molecule	NULL
(	NULL
12	NULL
)	NULL
;	NULL
PKB	NULL
,	NULL
protein	NULL
kinase	NULL
B	NULL
,	NULL
also	NULL
called	NULL
Akt	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
7108	NULL
stimulated	NULL
by	NULL
EBV	NULL
,	NULL
as	NULL
well	NULL
as	NULL
EBV-induced	NULL
immortalization	NULL
of	NULL
these	NULL
cells	NULL
with	NULL
the	NULL
same	NULL
dose-response	NULL
curve	NULL
as	NULL
inhibition	NULL
of	NULL
T	NULL
cell	NULL
proliferation	NULL
(	NULL
Golay	NULL
et	NULL
al	NULL
.	NULL

,	NULL
unpublished	NULL
data	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
PNU156804	NULL
shows	NULL
the	NULL
same	NULL
biological	NULL
activity	NULL
as	NULL
UP	NULL
in	NULL
vitro	NULL
on	NULL
human	NULL
lymphocytes	NULL
.	NULL

The	NULL
capacity	NULL
to	NULL
block	NULL
the	NULL
immortalization	NULL
of	NULL
B	NULL
lymphocytes	NULL
by	NULL
EBV	NULL
is	NULL
an	NULL
important	NULL
advantage	NULL
for	NULL
a	NULL
candidate	NULL
immunosuppressive	NULL
drug	NULL
due	NULL
to	NULL
the	NULL
frequent	NULL
occurrence	NULL
of	NULL
EBV-induced	NULL
lymphomas	NULL
in	NULL
immunosuppressed	NULL
patients	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
profile	NULL
and	NULL
cell	NULL
cycle-regulated	NULL
genes	NULL
in	NULL
PNU156804-treated	NULL
T	NULL
cells	NULL
has	NULL
allowed	NULL
us	NULL
to	NULL
conclude	NULL
that	NULL
PNU156804	NULL
blocks	NULL
T	NULL
cell	NULL
proliferation	NULL
in	NULL
mid-late	NULL
G	NULL
,	NULL
,	NULL
suggesting	NULL
that	NULL
that	NULL
its	NULL
target	NULL
is	NULL
very	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
UP	NULL
(	NULL
5	NULL
)	NULL
.	NULL

In	NULL
particular	NULL
we	NULL
show	NULL
that	NULL
PNU156804	NULL
inhibits	NULL
cells	NULL
between	NULL
cyclin	NULL
D2	NULL
and	NULL
cyclin	NULL
E	NULL
expression	NULL
and	NULL
that	NULL
both	NULL
cdk2	NULL
and	NULL
edk4	NULL
are	NULL
completely	NULL
inhibited	NULL
(	NULL
5	NULL
,	NULL
24	NULL
,	NULL
25	NULL
)	NULL
.	NULL

Furthermore	NULL
we	NULL
show	NULL
that	NULL
retinoblastoma	NULL
protein	NULL
remains	NULL
hypophosphorylated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PNU156804	NULL
(	NULL
5	NULL
,	NULL
26	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
PNU156804	NULL
does	NULL
not	NULL
inhibit	NULL
the	NULL
down-regulation	NULL
of	NULL
p27	NULL
protein	NULL
,	NULL
clearly	NULL
distinguishing	NULL
it	NULL
from	NULL
rapamycin	NULL
,	NULL
which	NULL
on	NULL
the	NULL
contrary	NULL
blocks	NULL
p27	NULL
degradation	NULL
(	NULL
19	NULL
,	NULL
27	NULL
,	NULL
28	NULL
)	NULL
.	NULL

Thus	NULL
the	NULL
prodigiosin	NULL
family	NULL
represents	NULL
a	NULL
new	NULL
family	NULL
of	NULL
molecules	NULL
with	NULL
a	NULL
common	NULL
mechanism	NULL
of	NULL
action	NULL
and	NULL
specific	NULL
molecular	NULL
targets	NULL
.	NULL

The	NULL
second	NULL
part	NULL
was	NULL
aimed	NULL
at	NULL
identifying	NULL
more	NULL
precisely	NULL
possible	NULL
target	NULL
proteins	NULL
of	NULL
PNU156804	NULL
action	NULL
.	NULL

We	NULL
have	NULL
first	NULL
demonstrated	NULL
that	NULL
PNU156804	NULL
blocks	NULL
IL-2-dependent	NULL
signaling	NULL
.	NULL

It	NULL
does	NULL
not	NULL
inhibit	NULL
significantly	NULL
the	NULL
induction	NULL
of	NULL
IL-2	NULL
and	NULL
of	NULL
its	NULL
receptor	NULL
a-and	NULL
y-chains	NULL
but	NULL
efficiently	NULL
blocks	NULL
IL-2-dependent	NULL
T	NULL
cell	NULL
proliferation	NULL
.	NULL

These	NULL
data	NULL
led	NULL
to	NULL
the	NULL
investigation	NULL
of	NULL
the	NULL
different	NULL
signaling	NULL
pathways	NULL
known	NULL
to	NULL
be	NULL
triggered	NULL
by	NULL
IL-2	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

IL-2	NULL
responses	NULL
are	NULL
mediated	NULL
by	NULL
the	NULL
IL-2R	NULL
complex	NULL
,	NULL
which	NULL
is	NULL
composed	NULL
of	NULL
three	NULL
subunits	NULL
,	NULL
«	NULL
,	NULL
3	NULL
,	NULL
and	NULL
y	NULL
(	NULL
8	NULL
,	NULL
9	NULL
,	NULL
29	NULL
)	NULL
.	NULL

The	NULL
-chain	NULL
is	NULL
responsible	NULL
for	NULL
high	NULL
affinity	NULL
IL-2	NULL
binding	NULL
,	NULL
whereas	NULL
the	NULL
B-	NULL
and	NULL
y-chains	NULL
mediate	NULL
signaling	NULL
(	NULL
8	NULL
,	NULL
9	NULL
)	NULL
.	NULL

Several	NULL
non-receptor	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
such	NULL
as	NULL
Jak1	NULL
,	NULL
Jak3	NULL
,	NULL
p56	NULL
``	NULL
**	NULL
,	NULL
and	NULL
syk	NULL
interact	NULL
with	NULL
the	NULL
IL-2R	NULL
and	NULL
become	NULL
activated	NULL
after	NULL
IL-2	NULL
engagement	NULL
(	NULL
8	NULL
,	NULL
9	NULL
,	NULL
19	NULL
,	NULL
29-33	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

10	NULL
)	NULL
.	NULL

IL-2	NULL
also	NULL
activates	NULL
PI3-kinase	NULL
(	NULL
9	NULL
,	NULL
19	NULL
,	NULL
22	NULL
,	NULL
34	NULL
,	NULL
35	NULL
)	NULL
.	NULL

These	NULL
different	NULL
kinases	NULL
in	NULL
turn	NULL
activate	NULL
different	NULL
cascades	NULL
that	NULL
lead	NULL
both	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
c-myc	NULL
,	NULL
c-fos	NULL
,	NULL
and	NULL
c-jun	NULL
,	NULL
which	NULL
form	NULL
the	NULL
transcription	NULL
factors	NULL
AP-1	NULL
and	NULL
bel-2	NULL
,	NULL
and	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
STAT	NULL
transcription	NULL
factors	NULL
(	NULL
10	NULL
,	NULL
12	NULL
,	NULL
13	NULL
,	NULL
29	NULL
,	NULL
30	NULL
,	NULL
33	NULL
,	NULL
36-39	NULL
)	NULL
.	NULL

IL-2	NULL
has	NULL
also	NULL
been	NULL
shown	NULL
to	NULL
activate	NULL
NF-KB	NULL
(	NULL
9	NULL
,	NULL
40	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

10	NULL
)	NULL
.	NULL

The	NULL
serine	NULL
rich	NULL
(	NULL
S	NULL
)	NULL
region	NULL
of	NULL
the	NULL
IL-2	NULL
-chain	NULL
is	NULL
known	NULL
to	NULL
associate	NULL
with	NULL
Jak1	NULL
and	NULL
syk	NULL
and	NULL
to	NULL
be	NULL
required	NULL
for	NULL
induction	NULL
of	NULL
c-mye	NULL
and	NULL
bel-2	NULL
(	NULL
9	NULL
,	NULL
29	NULL
,	NULL
36	NULL
)	NULL
.	NULL

The	NULL
acidic	NULL
domain	NULL
(	NULL
A	NULL
)	NULL
is	NULL
required	NULL
for	NULL
activation	NULL
of	NULL
p56	NULL
``	NULL
**	NULL
,	NULL
for	NULL
association	NULL
of	NULL
the	NULL
adapter	NULL
protein	NULL
she	NULL
,	NULL
which	NULL
may	NULL
mediate	NULL
activation	NULL
of	NULL
p21ras	NULL
and	NULL
of	NULL
the	NULL
MAPK	NULL
cascades	NULL
,	NULL
and	NULL
for	NULL
induction	NULL
of	NULL
c-fos	NULL
and	NULL
c-jun	NULL
gene	NULL
expression	NULL
(	NULL
9	NULL
,	NULL
13	NULL
,	NULL
29	NULL
,	NULL
31	NULL
,	NULL
41	NULL
)	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
activation	NULL
of	NULL
PI3-kinase	NULL
is	NULL
still	NULL
unclear	NULL
but	NULL
requires	NULL
the	NULL
S	NULL
region	NULL
and	NULL
leads	NULL
to	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
B	NULL
(	NULL
PKB	NULL
,	NULL
also	NULL
called	NULL
Akt	NULL
)	NULL
,	NULL
which	NULL
may	NULL
participate	NULL
in	NULL
induction	NULL
of	NULL
bel-2	NULL
and	NULL
down-regulation	NULL
of	NULL
p27	NULL
(	NULL
22	NULL
,	NULL
34	NULL
,	NULL
37	NULL
)	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
activation	NULL
of	NULL
NF-KB	NULL
is	NULL
still	NULL
unclear	NULL
but	NULL
may	NULL
involve	NULL
kinases	NULL
of	NULL
the	NULL
JNK	NULL
pathway	NULL
and	NULL
in	NULL
particular	NULL
MEKK-1	NULL
(	NULL
15	NULL
,	NULL
16	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

10	NULL
)	NULL
.	NULL

Evidence	NULL
has	NULL
been	NULL
presented	NULL
that	NULL
activation	NULL
of	NULL
c-myc	NULL
,	NULL
AP-1	NULL
,	NULL
and	NULL
bel-2	NULL
is	NULL
important	NULL
for	NULL
the	NULL
proliferative	NULL
response	NULL
of	NULL
T	NULL
cells	NULL
to	NULL
IL-2	NULL
(	NULL
13	NULL
,	NULL
29	NULL
,	NULL
42	NULL
,	NULL
43	NULL
)	NULL
.	NULL

Here	NULL
we	NULL
confirmed	NULL
bel-2	NULL
and	NULL
c-myc	NULL
induction	NULL
by	NULL
IL-2	NULL
in	NULL
our	NULL
IL-2-dependent	NULL
system	NULL
,	NULL
but	NULL
we	NULL
showed	NULL
that	NULL
PNU156804	NULL
does	NULL
not	NULL
affect	NULL
the	NULL
expression	NULL
of	NULL
these	NULL
genes	NULL
.	NULL

These	NULL
data	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
lack	NULL
of	NULL
inhibition	NULL
of	NULL
p27	NULL
down-regulation	NULL
,	NULL
suggest	NULL
that	NULL
the	NULL
Syk	NULL
and	NULL
PT3-kinase	NULL
pathways	NULL
possibly	NULL
involved	NULL
in	NULL
the	NULL
signaling	NULL
of	NULL
IL-2	NULL
to	NULL
these	NULL
molecules	NULL
are	NULL
not	NULL
targets	NULL
of	NULL
PNU156804	NULL
action	NULL
(	NULL
Fig	NULL
.	NULL

10	NULL
)	NULL
.	NULL

On	NULL
the	NULL
contrary	NULL
,	NULL
PNU156804	NULL
very	NULL
efficiently	NULL
inhibits	NULL
both	NULL
NF-KB	NULL
and	NULL
AP-1	NULL
activation	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
confirm	NULL
that	NULL
a	NULL
major	NULL
NF-kB	NULL
complex	NULL
induced	NULL
by	NULL
IL-2	NULL
in	NULL
our	NULL
primary	NULL
T	NULL
cell	NULL
INHIBITION	NULL
OF	NULL
IL-2-DEPENDENT	NULL
SIGNALING	NULL
BY	NULL
PNU156804	NULL
system	NULL
is	NULL
the	NULL
p50/p65	NULL
(	NULL
relA	NULL
)	NULL
complex	NULL
and	NULL
show	NULL
that	NULL
IL-2	NULL
signaling	NULL
leads	NULL
to	NULL
rapid	NULL
down-regulation	NULL
of	NULL
IkB-a	NULL
and	NULL
IkB-	NULL
$	NULL
B	NULL
,	NULL
as	NULL
described	NULL
for	NULL
many	NULL
of	NULL
the	NULL
other	NULL
signals	NULL
that	NULL
activate	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
15	NULL
,	NULL
16	NULL
,	NULL
44	NULL
)	NULL
.	NULL

Finally	NULL
we	NULL
demonstrate	NULL
that	NULL
PNU156804	NULL
inhibits	NULL
the	NULL
IL-2-induced	NULL
down-regulation	NULL
of	NULL
IxB-	NULL
«	NULL
and	NULL
IxB-	NULL
$	NULL
B	NULL
.	NULL

These	NULL
data	NULL
strongly	NULL
suggest	NULL
that	NULL
PNU156804	NULL
inhibits	NULL
NF-KB	NULL
activation	NULL
through	NULL
inhibition	NULL
of	NULL
IxB-a	NULL
and	NULL
IxB-B	NULL
down-regulation	NULL
.	NULL

IxB-a	NULL
and	NULL
IKB-B	NULL
are	NULL
thought	NULL
to	NULL
undergo	NULL
phosphorylation	NULL
by	NULL
IB	NULL
kinase	NULL
complex	NULL
(	NULL
es	NULL
)	NULL
,	NULL
and	NULL
this	NULL
phosphorylation	NULL
event	NULL
renders	NULL
these	NULL
proteins	NULL
targets	NULL
for	NULL
protea-some-mediated	NULL
protein	NULL
degradation	NULL
(	NULL
15	NULL
,	NULL
16	NULL
,	NULL
44	NULL
)	NULL
.	NULL

It	NULL
is	NULL
likely	NULL
that	NULL
many	NULL
second	NULL
messengers	NULL
can	NULL
trigger	NULL
these	NULL
phosphorylation	NULL
events	NULL
through	NULL
activation	NULL
of	NULL
perhaps	NULL
several	NULL
IB	NULL
kinases	NULL
,	NULL
since	NULL
many	NULL
different	NULL
signals	NULL
can	NULL
activate	NULL
NF-KB	NULL
in	NULL
different	NULL
cells	NULL
,	NULL
including	NULL
TNF	NULL
,	NULL
IL-1	NULL
,	NULL
LPS	NULL
,	NULL
phorbol	NULL
esters	NULL
,	NULL
anti-CD28	NULL
,	NULL
etc	NULL
.	NULL

All	NULL
signals	NULL
,	NULL
however	NULL
,	NULL
appear	NULL
to	NULL
act	NULL
by	NULL
degrading	NULL
IB	NULL
molecules	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
a	NULL
ubiquination-sensitive	NULL
IB	NULL
kinase	NULL
complex	NULL
has	NULL
been	NULL
described	NULL
,	NULL
and	NULL
two	NULL
IB	NULL
kinases	NULL
have	NULL
been	NULL
cloned	NULL
that	NULL
are	NULL
part	NULL
of	NULL
a	NULL
different	NULL
multiprotein	NULL
complex	NULL
(	NULL
45-47	NULL
)	NULL
.	NULL

Little	NULL
is	NULL
known	NULL
about	NULL
the	NULL
second	NULL
messengers	NULL
that	NULL
are	NULL
triggered	NULL
by	NULL
IL-2	NULL
and	NULL
lead	NULL
to	NULL
NF-KB	NULL
activation	NULL
and	NULL
about	NULL
which	NULL
IB	NULL
kinase	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
IL-2-induced	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
(	NULL
9	NULL
,	NULL
40	NULL
)	NULL
.	NULL

The	NULL
data	NULL
presented	NULL
here	NULL
suggest	NULL
that	NULL
PNU156804	NULL
inhibits	NULL
an	NULL
IL-2-specific	NULL
signaling	NULL
pathway	NULL
that	NULL
leads	NULL
to	NULL
IkB-a	NULL
and	NULL
IxB-	NULL
degradation	NULL
and	NULL
which	NULL
is	NULL
not	NULL
shared	NULL
by	NULL
PMA	NULL
or	NULL
PHA	NULL
,	NULL
since	NULL
PNU156804	NULL
did	NULL
not	NULL
inhibit	NULL
PMA-	NULL
or	NULL
PHA-induced	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

Furthermore	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
thought	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
IL-2	NULL
and	NULL
IL-2Ra	NULL
transcription	NULL
(	NULL
15	NULL
)	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
expression	NULL
of	NULL
these	NULL
two	NULL
genes	NULL
was	NULL
little	NULL
affected	NULL
by	NULL
PNU156804	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
a	NULL
specific	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
downstream	NULL
from	NULL
the	NULL
interaction	NULL
between	NULL
IL-2	NULL
and	NULL
its	NULL
receptor	NULL
.	NULL

Numerous	NULL
signals	NULL
can	NULL
,	NULL
however	NULL
,	NULL
lead	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
in	NULL
different	NULL
cells	NULL
.	NULL

The	NULL
experiments	NULL
presented	NULL
suggest	NULL
that	NULL
PNU156804	NULL
can	NULL
also	NULL
inhibit	NULL
NF-	NULL
«	NULL
B	NULL
induction	NULL
by	NULL
CD40	NULL
Abs	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
inhibition	NULL
of	NULL
NF-KB	NULL
activation	NULL
by	NULL
PNU156804	NULL
is	NULL
not	NULL
specific	NULL
solely	NULL
for	NULL
the	NULL
IL-2-dependent	NULL
signaling	NULL
pathway	NULL
.	NULL

A	NULL
complete	NULL
investigation	NULL
of	NULL
the	NULL
different	NULL
signals	NULL
and	NULL
intracellular	NULL
cascades	NULL
that	NULL
lead	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
in	NULL
different	NULL
cell	NULL
types	NULL
and	NULL
their	NULL
sensitivity	NULL
to	NULL
PNU156804	NULL
will	NULL
be	NULL
of	NULL
particular	NULL
interest	NULL
in	NULL
identifying	NULL
a	NULL
molecular	NULL
target	NULL
for	NULL
PNU156804	NULL
but	NULL
is	NULL
clearly	NULL
beyond	NULL
the	NULL
scope	NULL
of	NULL
this	NULL
article	NULL
.	NULL

Although	NULL
much	NULL
more	NULL
information	NULL
is	NULL
available	NULL
on	NULL
the	NULL
IL-2-induced	NULL
activation	NULL
of	NULL
AP-1	NULL
activity	NULL
,	NULL
the	NULL
exact	NULL
signaling	NULL
pathways	NULL
have	NULL
not	NULL
yet	NULL
been	NULL
clearly	NULL
identified	NULL
(	NULL
8	NULL
,	NULL
13	NULL
,	NULL
14	NULL
,	NULL
29	NULL
,	NULL
31	NULL
,	NULL
35	NULL
,	NULL
48	NULL
)	NULL
.	NULL

AP-1	NULL
activation	NULL
is	NULL
regulated	NULL
at	NULL
different	NULL
levels	NULL
,	NULL
involving	NULL
transcription	NULL
of	NULL
its	NULL
components	NULL
such	NULL
as	NULL
c-fos	NULL
and	NULL
c-jun	NULL
and	NULL
activation	NULL
of	NULL
c-jun	NULL
through	NULL
phosphorylation	NULL
by	NULL
JNK	NULL
(	NULL
13	NULL
,	NULL
14	NULL
,	NULL
48	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
activation	NULL
of	NULL
ras	NULL
through	NULL
the	NULL
p56	NULL
``	NULL
*	NULL
and	NULL
the	NULL
she	NULL
,	NULL
sos	NULL
,	NULL
grb	NULL
pathways	NULL
and	NULL
possibly	NULL
through	NULL
the	NULL
action	NULL
of	NULL
other	NULL
IL-2-associated	NULL
kinases	NULL
can	NULL
lead	NULL
to	NULL
activation	NULL
of	NULL
the	NULL
MAP	NULL
kinase	NULL
(	NULL
ERK	NULL
)	NULL
and	NULL
JNK	NULL
pathways	NULL
,	NULL
which	NULL
are	NULL
required	NULL
for	NULL
maximal	NULL
AP-1	NULL
activation	NULL
(	NULL
13	NULL
,	NULL
14	NULL
,	NULL
38	NULL
,	NULL
43	NULL
,	NULL
48-50	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

10	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
exact	NULL
target	NULL
of	NULL
PNU156804	NULL
that	NULL
leads	NULL
to	NULL
AP-1	NULL
inhibition	NULL
will	NULL
require	NULL
a	NULL
more	NULL
detailed	NULL
characterization	NULL
of	NULL
its	NULL
effects	NULL
on	NULL
these	NULL
kinase	NULL
cascades	NULL
,	NULL
which	NULL
is	NULL
beyond	NULL
the	NULL
scope	NULL
of	NULL
this	NULL
paper	NULL
.	NULL

It	NULL
is	NULL
again	NULL
of	NULL
particular	NULL
interest	NULL
that	NULL
PNU156804	NULL
specifically	NULL
blocks	NULL
the	NULL
IL-2-	NULL
and	NULL
not	NULL
PMA-induced	NULL
AP-1	NULL
activation	NULL
,	NULL
suggesting	NULL
a	NULL
specific	NULL
effect	NULL
on	NULL
a	NULL
target	NULL
downstream	NULL
from	NULL
IL-2	NULL
.	NULL

Interestingly	NULL
MEKK-1	NULL
,	NULL
a	NULL
kinase	NULL
that	NULL
is	NULL
upstream	NULL
from	NULL
the	NULL
JNK	NULL
cascade	NULL
and	NULL
therefore	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
AP-1	NULL
activation	NULL
,	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
activate	NULL
NF-	NULL
«	NULL
B	NULL
through	NULL
activation	NULL
of	NULL
one	NULL
or	NULL
more	NULL
IB	NULL
kinase	NULL
complexes	NULL
(	NULL
15	NULL
,	NULL
23	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
AP-1	NULL
and	NULL
NF-KB	NULL
pathways	NULL
appear	NULL
to	NULL
be	NULL
linked	NULL
by	NULL
MEKK-1	NULL
(	NULL
Fig	NULL
.	NULL

10	NULL
)	NULL
.	NULL

It	NULL
is	NULL
tempting	NULL
to	NULL
speculate	NULL
that	NULL
a	NULL
target	NULL
of	NULL
PNU156804	NULL
could	NULL
lie	NULL
in	NULL
the	NULL
pathway	NULL
linking	NULL
the	NULL
IL-2	NULL
receptor	NULL
to	NULL
such	NULL
a	NULL
dual	NULL
kinase	NULL
capable	NULL
of	NULL
activating	NULL
both	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
AP-1	NULL
pathways	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
We	NULL
conclude	NULL
that	NULL
the	NULL
prodigiosin	NULL
family	NULL
of	NULL
drugs	NULL
show	NULL
a	NULL
very	NULL
specific	NULL
effect	NULL
on	NULL
IL-2-induced	NULL
signaling	NULL
,	NULL
leading	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
AP-1	NULL
activation	NULL
.	NULL

These	NULL
two	NULL
transcription	NULL
factor	NULL
complexes	NULL
appear	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
control	NULL
of	NULL
several	NULL
cellular	NULL
functions	NULL
,	NULL
including	NULL
proliferation	NULL
and	NULL
apoptosis	NULL
(	NULL
8	NULL
,	NULL
29	NULL
,	NULL
36	NULL
,	NULL
51	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
we	NULL
hypothesize	NULL
that	NULL
inhibition	NULL
of	NULL
AP-1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
may	NULL
be	NULL
responsible	NULL
at	NULL
least	NULL
in	NULL
part	NULL
for	NULL
the	NULL
proliferation	NULL
block	NULL
induced	NULL
by	NULL
prodigiosins	NULL
.	NULL

The	NULL
effi-cacy	NULL
,	NULL
specificity	NULL
of	NULL
action	NULL
,	NULL
and	NULL
diversity	NULL
relative	NULL
to	NULL
other	NULL
known	NULL
immunosuppressive	NULL
drugs	NULL
make	NULL
this	NULL
family	NULL
of	NULL
compounds	NULL
of	NULL
great	NULL
interest	NULL
for	NULL
further	NULL
preclinical	NULL
studies	NULL
,	NULL
as	NULL
well	NULL
as	NULL
interesting	NULL
tools	NULL
to	NULL
further	NULL
dissect	NULL
the	NULL
signaling	NULL
pathways	NULL
triggered	NULL
by	NULL
IL-2	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
centrality	NULL
of	NULL
IL-2	NULL
signaling	NULL
and	NULL
AP-1	NULL
and	NULL
NF-KB	NULL
activation	NULL
in	NULL
the	NULL
biology	NULL
of	NULL
T	NULL
and	NULL
other	NULL
cell	NULL
types	NULL
makes	NULL
this	NULL
class	NULL
of	NULL
compounds	NULL
of	NULL
wide	NULL
interest	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Dr.	NULL
A.	NULL
Sica	NULL
for	NULL
his	NULL
useful	NULL
advice	NULL
and	NULL
gift	NULL
of	NULL
Abs	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Calne	NULL
,	NULL
R.	NULL
Y.	NULL
,	NULL
S.	NULL
Thiru	NULL
,	NULL
P.	NULL
McMaster	NULL
,	NULL
G.	NULL
N.	NULL
Craddock	NULL
,	NULL
D.	NULL
J.	NULL
G.	NULL
White	NULL
,	NULL
D.	NULL
B.	NULL
Evans	NULL
,	NULL
D.	NULL
C.	NULL
Dunn	NULL
,	NULL
and	NULL
B.	NULL
D.	NULL
Pentlow	NULL
.	NULL

1978	NULL
.	NULL

Cyclosporin	NULL
A	NULL
in	NULL
patients	NULL
receiving	NULL
renal	NULL
allografts	NULL
from	NULL
cadaver	NULL
donors	NULL
.	NULL

Lancet	NULL
2:1323	NULL
.	NULL

2	NULL
.	NULL

Canadian	NULL
Multicenter	NULL
Transplant	NULL
Study	NULL
Group	NULL
.	NULL

1986	NULL
.	NULL

A	NULL
randomized	NULL
clinical	NULL
trial	NULL
of	NULL
cyclosporin	NULL
in	NULL
cadaveric	NULL
renal	NULL
transplantation	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

314:1219	NULL
.	NULL

3	NULL
.	NULL

Sigal	NULL
,	NULL
N.	NULL
H.	NULL
,	NULL
and	NULL
F.	NULL
J.	NULL
Dumont	NULL
.	NULL

1992	NULL
.	NULL

Cyclosporin	NULL
A	NULL
,	NULL
FK-506	NULL
,	NULL
and	NULL
rapamycin	NULL
:	NULL
pharmacological	NULL
probes	NULL
of	NULL
lymphocyte	NULL
signal	NULL
transduction	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

10:519	NULL
.	NULL

4	NULL
.	NULL

Thomson	NULL
,	NULL
A.	NULL
W.	NULL
,	NULL
and	NULL
T.	NULL
E.	NULL
Starzl	NULL
.	NULL

1993	NULL
.	NULL

New	NULL
immunosuppressive	NULL
drugs	NULL
:	NULL
mechanistic	NULL
insights	NULL
and	NULL
potential	NULL
therapeutic	NULL
advances	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

136:72	NULL
.	NULL

5	NULL
.	NULL

Songia	NULL
,	NULL
S.	NULL
,	NULL
A.	NULL
Mortellaro	NULL
,	NULL
S.	NULL
Taverna	NULL
,	NULL
C.	NULL
Fomnasiero	NULL
,	NULL
E.	NULL
Scheiber	NULL
,	NULL
E.	NULL
Erba	NULL
,	NULL
F.	NULL
Colotta	NULL
,	NULL
A.	NULL
Mantovani	NULL
,	NULL
A.	NULL
M.	NULL
Isetta	NULL
,	NULL
and	NULL
J.	NULL
Golay	NULL
.	NULL

1997	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
new	NULL
immunosuppressive	NULL
drug	NULL
undecylprodigiosin	NULL
in	NULL
human	NULL
lymphocytes	NULL
:	NULL
retinoblastoma	NULL
protein	NULL
,	NULL
cyclin-dependent	NULL
kinase-2	NULL
,	NULL
and	NULL
cyclin-dependent	NULL
ki-nase-4	NULL
as	NULL
molecular	NULL
targets	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

158:3987	NULL
.	NULL

6	NULL
.	NULL

Golay	NULL
,	NULL
J.	NULL
,	NULL
G.	NULL
Cusmano	NULL
,	NULL
and	NULL
M.	NULL
Introna	NULL
.	NULL

1992	NULL
.	NULL

Independent	NULL
regulation	NULL
of	NULL
c-myc	NULL
,	NULL
B-myb	NULL
,	NULL
and	NULL
c-myb	NULL
gene	NULL
expression	NULL
by	NULL
inducers	NULL
and	NULL
inhibitors	NULL
of	NULL
proliferation	NULL
in	NULL
human	NULL
B	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

149:300	NULL
.	NULL

7	NULL
.	NULL

Golay	NULL
,	NULL
J.	NULL
,	NULL
E.	NULL
Erba	NULL
,	NULL
S.	NULL
Bernasconi	NULL
,	NULL
G.	NULL
Peri	NULL
,	NULL
and	NULL
M.	NULL
Introna	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
A-myb	NULL
gene	NULL
is	NULL
preferentially	NULL
expressed	NULL
in	NULL
tonsillar	NULL
CD38	NULL
*	NULL
,	NULL
€CD39~	NULL
,	NULL
and	NULL
sIgM~	NULL
B	NULL
lymphocytes	NULL
and	NULL
in	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cell	NULL
lines	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

153:543	NULL
.	NULL

8	NULL
.	NULL

Theze	NULL
,	NULL
J.	NULL
,	NULL
P.	NULL
M.	NULL
Alzari	NULL
,	NULL
and	NULL
J.	NULL
Bertoglio	NULL
.	NULL

1996	NULL
.	NULL

Interleukin	NULL
2	NULL
and	NULL
its	NULL
receptor	NULL
:	NULL
recent	NULL
advances	NULL
and	NULL
new	NULL
immunological	NULL
functions	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
17:481	NULL
.	NULL

9	NULL
.	NULL

Rebollo	NULL
,	NULL
A.	NULL
,	NULL
J.	NULL
Gomez	NULL
,	NULL
and	NULL
C.	NULL
Martinez-A	NULL
.	NULL

1996	NULL
.	NULL

Lessons	NULL
from	NULL
immunological	NULL
,	NULL
biochemical	NULL
and	NULL
molecular	NULL
pathways	NULL
of	NULL
the	NULL
activation	NULL
mediated	NULL
by	NULL
IL-2	NULL
and	NULL
IL-4	NULL
.	NULL

Adv	NULL
.	NULL

Immunol	NULL
.	NULL

63:127	NULL
.	NULL

10	NULL
.	NULL

Beadling	NULL
,	NULL
C.	NULL
,	NULL
J.	NULL
Babbage	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Cantrell	NULL
.	NULL

1994	NULL
.	NULL

Activation	NULL
of	NULL
Jak	NULL
kinases	NULL
and	NULL
STAT	NULL
proteins	NULL
by	NULL
Interleukin-2	NULL
and	NULL
interferon-	NULL
«	NULL
,	NULL
but	NULL
not	NULL
the	NULL
T	NULL
cell	NULL
antigen	NULL
re-ceptor	NULL
,	NULL
in	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:5605	NULL
.	NULL

11	NULL
.	NULL

O'Shea	NULL
,	NULL
J.	NULL
J	NULL
.	NULL

1997	NULL
.	NULL

Jaks	NULL
,	NULL
STAT	NULL
's	NULL
,	NULL
cytokine	NULL
signal	NULL
transduction	NULL
,	NULL
and	NULL
immunoregu-lation	NULL
:	NULL
are	NULL
we	NULL
there	NULL
yet	NULL
?	NULL

Immunity	NULL
7:1	NULL
.	NULL

12	NULL
.	NULL

Takeshita	NULL
,	NULL
T.	NULL
,	NULL
T.	NULL
Arita	NULL
,	NULL
M.	NULL
Higuchi	NULL
,	NULL
H.	NULL
Asao	NULL
,	NULL
K.	NULL
Endo	NULL
,	NULL
H.	NULL
Kuroda	NULL
,	NULL
N.	NULL
Tanaka	NULL
,	NULL
K.	NULL
Murata	NULL
,	NULL
N.	NULL
Ishii	NULL
,	NULL
and	NULL
K.	NULL
Sugamura	NULL
.	NULL

1997	NULL
.	NULL

STAM	NULL
,	NULL
signal	NULL
transducing	NULL
adaptor	NULL
molecule	NULL
,	NULL
is	NULL
associated	NULL
with	NULL
Janus	NULL
kinases	NULL
and	NULL
involved	NULL
in	NULL
signaling	NULL
for	NULL
cell	NULL
growth	NULL
and	NULL
c-myc	NULL
induction	NULL
.	NULL

Immunity	NULL
6:449	NULL
.	NULL

13	NULL
.	NULL

Pastor	NULL
,	NULL
M.	NULL
L	NULL
,	NULL
K.	NULL
Reif	NULL
,	NULL
and	NULL
D.	NULL
Cantrell	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
regulation	NULL
and	NULL
function	NULL
of	NULL
p21ras	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
and	NULL
growth	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
16:159	NULL
.	NULL

14	NULL
.	NULL

Robinson	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
M.	NULL
H.	NULL
Cobb	NULL
.	NULL

1997	NULL
.	NULL

Mitogen-activated	NULL
protein	NULL
kinase	NULL
pathways	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

9:180	NULL
.	NULL

15	NULL
.	NULL

May	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
S.	NULL
Ghosh	NULL
.	NULL

198	NULL
.	NULL

Signal	NULL
transduction	NULL
through	NULL
NF-kB	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
19:80	NULL
.	NULL

16	NULL
.	NULL

Maniatis	NULL
,	NULL
T.	NULL
1997	NULL
.	NULL

Catalysis	NULL
by	NULL
a	NULL
multiprotein	NULL
IB	NULL
kinase	NULL
complex	NULL
.	NULL

Science	NULL
278:818	NULL
.	NULL

17	NULL
.	NULL

Tsuji	NULL
,	NULL
R.	NULL
F.	NULL
,	NULL
M.	NULL
Yamamoto	NULL
,	NULL
A.	NULL
Nakamura	NULL
,	NULL
T.	NULL
Kataoka	NULL
,	NULL
J.	NULL
Magae	NULL
,	NULL
K.	NULL
Nagai	NULL
,	NULL
and	NULL
M.	NULL
Yamasaki	NULL
.	NULL

1990	NULL
.	NULL

Selective	NULL
immunosuppression	NULL
of	NULL
Prodigiosin	NULL
25-C	NULL
and	NULL
FK506	NULL
in	NULL
the	NULL
murine	NULL
immune	NULL
system	NULL
.	NULL

J.	NULL
Antibiot	NULL
.	NULL

(	NULL
Tokyo	NULL
)	NULL
43:1293	NULL
.	NULL

18	NULL
.	NULL

Tsuji	NULL
,	NULL
R.	NULL
F.	NULL
,	NULL
J.	NULL
Magac	NULL
,	NULL
M.	NULL
Yamashita	NULL
,	NULL
K.	NULL
Nagai	NULL
,	NULL
and	NULL
M.	NULL
Yamasaki	NULL
.	NULL

1992	NULL
.	NULL

Im-munomodulating	NULL
properties	NULL
of	NULL
Prodigiosin	NULL
25-C	NULL
,	NULL
an	NULL
antibiotic	NULL
which	NULL
preferentially	NULL
suppresses	NULL
induction	NULL
of	NULL
cytotoxic	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Antibiot	NULL
.	NULL

(	NULL
Tokyo	NULL
)	NULL
45:1295	NULL
.	NULL

19	NULL
.	NULL

Abraham	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Wiederrecht	NULL
.	NULL

1996	NULL
.	NULL

Immunopharmacology	NULL
of	NULL
Rapamycin	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

14:483	NULL
.	NULL

20	NULL
.	NULL

Brazelton	NULL
,	NULL
T.	NULL
R.	NULL
,	NULL
and	NULL
R.	NULL
E.	NULL
Morris	NULL
.	NULL

1996	NULL
.	NULL

Molecular	NULL
mechanisms	NULL
of	NULL
action	NULL
of	NULL
new	NULL
xenobiotic	NULL
immunosuppressive	NULL
drugs	NULL
:	NULL
tacrolimus	NULL
(	NULL
FK506	NULL
)	NULL
,	NULL
sirolimus	NULL
(	NULL
rapamy-cin	NULL
)	NULL
,	NULL
mycophenolate	NULL
mofetil	NULL
and	NULL
leflunomide	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

8:710	NULL
.	NULL

21	NULL
.	NULL

Calvo	NULL
,	NULL
V.	NULL
,	NULL
C.	NULL
M.	NULL
Crews	NULL
,	NULL
T.	NULL
A.	NULL
Vik	NULL
,	NULL
and	NULL
B.	NULL
E.	NULL
Bieter	NULL
.	NULL

1992	NULL
.	NULL

Interleukin	NULL
2	NULL
stimulation	NULL
of	NULL
p70	NULL
S6	NULL
kinase	NULL
activity	NULL
is	NULL
inhibited	NULL
by	NULL
the	NULL
immunosuppressant	NULL
rapamycin	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:7571	NULL
.	NULL

22	NULL
.	NULL

Brennan	NULL
,	NULL
P.	NULL
,	NULL
J.	NULL
W.	NULL
Babbage	NULL
,	NULL
B.	NULL
M.	NULL
T.	NULL
Burgering	NULL
,	NULL
B.	NULL
Groner	NULL
,	NULL
K.	NULL
Reif	NULL
,	NULL
and	NULL
D.	NULL
Cantrell	NULL
.	NULL

1997	NULL
.	NULL

Phosphatidylinositol	NULL
3-kinase	NULL
couples	NULL
the	NULL
interleukin-2	NULL
receptor	NULL
to	NULL
the	NULL
cell	NULL
cycle	NULL
regulator	NULL
E2F	NULL
.	NULL

Immunity	NULL
7:679	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

7109	NULL
Lee	NULL
,	NULL
F.	NULL
S.	NULL
,	NULL
J.	NULL
Hagler	NULL
,	NULL
Z.	NULL
J.	NULL
Chen	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1997	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
IxB-	NULL
@	NULL
kinase	NULL
complex	NULL
by	NULL
MEKK1	NULL
,	NULL
a	NULL
kinase	NULL
of	NULL
the	NULL
JNK	NULL
pathway	NULL
.	NULL

Cell	NULL
88:213	NULL
.	NULL

Sherr	NULL
,	NULL
C.	NULL
J.1994	NULL
.	NULL

G	NULL
,	NULL
phase	NULL
progression	NULL
:	NULL
cycling	NULL
on	NULL
cue	NULL
.	NULL

Cell	NULL
79:551	NULL
.	NULL

Ajchenbaum	NULL
,	NULL
F.	NULL
,	NULL
K.	NULL
Ando	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
DeCaprio	NULL
,	NULL
and	NULL
J.	NULL
D.	NULL
Griffin	NULL
.	NULL

1993	NULL
.	NULL

Independent	NULL
regulation	NULL
of	NULL
human	NULL
D-type	NULL
cyclin	NULL
gene	NULL
expression	NULL
during	NULL
G	NULL
,	NULL
phase	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:4113	NULL
.	NULL

Furukawa	NULL
,	NULL
Y.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
DeCaprio	NULL
,	NULL
A.	NULL
Freedman	NULL
,	NULL
Y.	NULL
Kanakura	NULL
,	NULL
M.	NULL
Nakamura	NULL
,	NULL
T.	NULL
J.	NULL
Emst	NULL
,	NULL
D.	NULL
M.	NULL
Livingston	NULL
,	NULL
and	NULL
J.	NULL
D.	NULL
Griffin	NULL
.	NULL

1990	NULL
.	NULL

Expression	NULL
and	NULL
state	NULL
of	NULL
phosphorylation	NULL
of	NULL
the	NULL
retinoblastoma	NULL
susceptibility	NULL
gene	NULL
product	NULL
in	NULL
cycling	NULL
and	NULL
noncycling	NULL
human	NULL
haematopoietic	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87:2770	NULL
.	NULL

Nourse	NULL
,	NULL
J.	NULL
,	NULL
E.	NULL
Firpo	NULL
,	NULL
W.	NULL
M.	NULL
Flanagan	NULL
,	NULL
S.	NULL
Coats	NULL
,	NULL
K.	NULL
Polyak	NULL
,	NULL
M.	NULL
H.	NULL
Lee	NULL
,	NULL
J.	NULL
Massague	NULL
,	NULL
G.	NULL
R.	NULL
Crabtree	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Roberts	NULL
.	NULL

1994	NULL
.	NULL

Interleukin-2-mediated	NULL
elimination	NULL
of	NULL
the	NULL
p27kip1	NULL
cyclin-dependent	NULL
kinase	NULL
inhibitor	NULL
prevented	NULL
by	NULL
rapamycin	NULL
.	NULL

Nature	NULL
372:570	NULL
.	NULL

Firpo	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
A.	NULL
Koff	NULL
,	NULL
M.	NULL
J.	NULL
Solomon	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Roberts	NULL
.	NULL

1994	NULL
.	NULL

Inactivation	NULL
of	NULL
a	NULL
cdk2	NULL
inhibitor	NULL
during	NULL
interleukin	NULL
2-induced	NULL
proliferation	NULL
of	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

14:4889	NULL
.	NULL

Miyazaki	NULL
,	NULL
T.	NULL
,	NULL
Z.	NULL
J.	NULL
Liu	NULL
,	NULL
A.	NULL
Kawahara	NULL
,	NULL
Y.	NULL
Minami	NULL
,	NULL
K.	NULL
Yamada	NULL
,	NULL
Y.	NULL
Tsujimoto	NULL
,	NULL
E.	NULL
L.	NULL
Barsoumian	NULL
,	NULL
R.	NULL
M.	NULL
Perlmutter	NULL
,	NULL
and	NULL
T.	NULL
Taniguchi	NULL
.	NULL

1995	NULL
.	NULL

Three	NULL
distinct	NULL
IL-2	NULL
signaling	NULL
pathways	NULL
mediated	NULL
by	NULL
bel-2	NULL
,	NULL
c-myc	NULL
and	NULL
Ick	NULL
cooperate	NULL
in	NULL
hematopoietic	NULL
cell	NULL
proliferation	NULL
.	NULL

Cell	NULL
81:223	NULL
.	NULL

Minami	NULL
,	NULL
Y.	NULL
,	NULL
Y.	NULL
Nakagawa	NULL
,	NULL
A.	NULL
Kawahara	NULL
,	NULL
T.	NULL
Miyazaki	NULL
,	NULL
K.	NULL
Sada	NULL
,	NULL
H.	NULL
Yamamura	NULL
,	NULL
and	NULL
T.	NULL
Taniguchi	NULL
.	NULL

1995	NULL
.	NULL

Protein	NULL
tyrosine	NULL
kinase	NULL
Syk	NULL
is	NULL
associated	NULL
with	NULL
and	NULL
activated	NULL
by	NULL
the	NULL
IL-2	NULL
receptor	NULL
:	NULL
possible	NULL
link	NULL
in	NULL
the	NULL
c-myc	NULL
induction	NULL
pathway	NULL
.	NULL

Immunity	NULL
2:89	NULL
.	NULL

Tumer	NULL
,	NULL
B.	NULL
,	NULL
U.	NULL
Rapp	NULL
,	NULL
H.	NULL
App	NULL
,	NULL
M.	NULL
Greene	NULL
,	NULL
K.	NULL
Dobashi	NULL
,	NULL
and	NULL
J.	NULL
Reid	NULL
.	NULL

1991	NULL
.	NULL

Interleukin-2	NULL
induces	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
activation	NULL
of	NULL
p72-74	NULL
Raf-1	NULL
kinase	NULL
in	NULL
a	NULL
T	NULL
cell	NULL
line	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:1227	NULL
.	NULL

Witthuhn	NULL
,	NULL
B.	NULL
,	NULL
O.	NULL
Silvennoinen	NULL
,	NULL
O.	NULL
Miura	NULL
,	NULL
K.	NULL
Lai	NULL
,	NULL
C.	NULL
Cwik	NULL
,	NULL
E.	NULL
Liu	NULL
,	NULL
and	NULL
J.	NULL
Thle	NULL
.	NULL

1994	NULL
.	NULL

Involvement	NULL
of	NULL
the	NULL
Jak-3	NULL
Janus	NULL
kinase	NULL
in	NULL
signalling	NULL
by	NULL
interleukin	NULL
2	NULL
and	NULL
4	NULL
in	NULL
lymphoid	NULL
and	NULL
myeloid	NULL
cells	NULL
.	NULL

Nature	NULL
370:153	NULL
.	NULL

Johnston	NULL
,	NULL
J.	NULL
,	NULL
M.	NULL
Kawamura	NULL
,	NULL
R.	NULL
Kirken	NULL
,	NULL
Y.	NULL
Chen	NULL
,	NULL
T.	NULL
Blake	NULL
,	NULL
K.	NULL
Shibuya	NULL
,	NULL
J.	NULL
Ortaldo	NULL
,	NULL
D.	NULL
McVicar	NULL
,	NULL
and	NULL
J.	NULL
O'Shea	NULL
.	NULL

1994	NULL
.	NULL

Phosphorylation	NULL
and	NULL
activation	NULL
of	NULL
the	NULL
Jak-3	NULL
Janus	NULL
kinase	NULL
in	NULL
response	NULL
to	NULL
interleukin-2	NULL
.	NULL

Nature	NULL
370:151	NULL
.	NULL

Reif	NULL
,	NULL
K.	NULL
,	NULL
B.	NULL
M.	NULL
T.	NULL
Burgering	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Cantrell	NULL
.	NULL

1997	NULL
.	NULL

Phosphatidylinositol	NULL
3-kinase	NULL
links	NULL
the	NULL
interleukin-2	NULL
receptor	NULL
to	NULL
protein	NULL
kinase	NULL
B	NULL
and	NULL
p70	NULL
$	NULL
6	NULL
kinase	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272:14426	NULL
.	NULL

Karmnitz	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
L.	NULL
A.	NULL
Burns	NULL
,	NULL
S.	NULL
L.	NULL
Sutor	NULL
,	NULL
J.	NULL
Blenis	NULL
,	NULL
and	NULL
R.	NULL
T.	NULL
Abraham	NULL
.	NULL

1995	NULL
.	NULL

Interleukin-2	NULL
triggers	NULL
a	NULL
novel	NULL
phosphatidyl	NULL
3-kinase-dependent	NULL
MEK	NULL
activation	NULL
pathway	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

15:3049	NULL
.	NULL

Taniguchi	NULL
,	NULL
T.1995	NULL
.	NULL

Cytokine	NULL
signaling	NULL
through	NULL
nonreceptor	NULL
protein	NULL
tyrosine	NULL
ki-nases	NULL
.	NULL

Science	NULL
268:251	NULL
.	NULL

Abmed	NULL
,	NULL
N.	NULL
N.	NULL
,	NULL
H.	NULL
L.	NULL
Grimes	NULL
,	NULL
A.	NULL
Bellacosa	NULL
,	NULL
T.	NULL
O.	NULL
Chan	NULL
,	NULL
and	NULL
P.	NULL
N.	NULL
Tsichlis	NULL
.	NULL

1997	NULL
.	NULL

Transduction	NULL
of	NULL
interleukin-2	NULL
antiapoptotic	NULL
and	NULL
proliferative	NULL
signals	NULL
via	NULL
Akt	NULL
protein	NULL
kinase	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94:3627	NULL
.	NULL

Jacinto	NULL
,	NULL
E.	NULL
,	NULL
G.	NULL
Werlen	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1998	NULL
.	NULL

Cooperation	NULL
between	NULL
Syk	NULL
and	NULL
Racl	NULL
leads	NULL
to	NULL
synergistic	NULL
JNK	NULL
activation	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

Immunity	NULL
8:41	NULL
.	NULL

Fujii	NULL
,	NULL
H.	NULL
,	NULL
Y.	NULL
Nakagawa	NULL
,	NULL
U.	NULL
Schindler	NULL
,	NULL
A.	NULL
Kawahara	NULL
,	NULL
H.	NULL
Mori	NULL
,	NULL
F.	NULL
Gouilleux	NULL
,	NULL
B.	NULL
Groner	NULL
,	NULL
J.	NULL
N.	NULL
Thie	NULL
,	NULL
Y.	NULL
Minami	NULL
,	NULL
T.	NULL
Miyazaki	NULL
,	NULL
and	NULL
T.	NULL
Taniguchi	NULL
.	NULL

1995	NULL
.	NULL

Activation	NULL
of	NULL
Stat5	NULL
by	NULL
interleukin	NULL
2	NULL
requires	NULL
a	NULL
carboxyl-terminal	NULL
region	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
receptor	NULL
chain	NULL
but	NULL
is	NULL
not	NULL
essential	NULL
for	NULL
the	NULL
proliferative	NULL
signal	NULL
transmission	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92:5482	NULL
.	NULL

Arima	NULL
,	NULL
N.	NULL
,	NULL
W.	NULL
A.	NULL
Kuziel	NULL
,	NULL
T.	NULL
A.	NULL
Grdina	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1992	NULL
.	NULL

IL-2-induced	NULL
signal	NULL
transduction	NULL
involves	NULL
the	NULL
activation	NULL
of	NULL
nuclear	NULL
NF-KB	NULL
expression	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

148:83	NULL
,	NULL
Fairhurst	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
M.	NULL
Dacipour	NULL
,	NULL
M.	NULL
C.	NULL
Amaral	NULL
,	NULL
and	NULL
A.	NULL
E.	NULL
Nel	NULL
.	NULL

1993	NULL
.	NULL

Activation	NULL
of	NULL
mitogen-activated	NULL
protein	NULL
kinase/ERK-2	NULL
in	NULL
phytohaemagglutinin	NULL
in	NULL
blasts	NULL
by	NULL
recombinant	NULL
interleukin-2	NULL
:	NULL
contrasting	NULL
features	NULL
with	NULL
CD3	NULL
activation	NULL
.	NULL

Immunology	NULL
79:112	NULL
.	NULL

Zamorano	NULL
,	NULL
J.	NULL
,	NULL
H.	NULL
Y.	NULL
Wang	NULL
,	NULL
R.	NULL
Wang	NULL
,	NULL
Y.	NULL
Shi	NULL
,	NULL
G.	NULL
D.	NULL
Longmore	NULL
,	NULL
and	NULL
A.	NULL
D.	NULL
Keegan	NULL
.	NULL

1998	NULL
.	NULL

Regulation	NULL
of	NULL
cell	NULL
growth	NULL
by	NULL
IL-2	NULL
:	NULL
role	NULL
of	NULL
STATS	NULL
in	NULL
protection	NULL
from	NULL
apoptosis	NULL
but	NULL
not	NULL
in	NULL
cell	NULL
cycle	NULL
progression	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

160:3502	NULL
.	NULL

Crawley	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
L.	NULL
Rawlinson	NULL
,	NULL
F.	NULL
V.	NULL
Lali	NULL
,	NULL
T.	NULL
H.	NULL
Page	NULL
,	NULL
J.	NULL
Saklatvala	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
J.	NULL
Foxwell	NULL
.	NULL

1997	NULL
.	NULL

T	NULL
cell	NULL
proliferation	NULL
in	NULL
response	NULL
to	NULL
Interleukin	NULL
2	NULL
and	NULL
7	NULL
requires	NULL
p38	NULL
MAP	NULL
kinase	NULL
activation	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272:15023.	NULL
.	NULL

Stancovski	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1997	NULL
.	NULL

NF-B	NULL
activation	NULL
:	NULL
the	NULL
IxB	NULL
kinase	NULL
re	NULL
vealed	NULL
.	NULL

Cell	NULL
91:299	NULL
.	NULL

Wang	NULL
,	NULL
W.	NULL
,	NULL
W.	NULL
F.	NULL
Tam	NULL
,	NULL
C.	NULL
C.	NULL
W.	NULL
Hughes	NULL
,	NULL
S.	NULL
Rath	NULL
,	NULL
and	NULL
R.	NULL
Sen.	NULL
1997	NULL
.	NULL

C-rel	NULL
is	NULL
a	NULL
target	NULL
of	NULL
pentoxiffylline-mediated	NULL
inhibition	NULL
of	NULL
T	NULL
lymphocyte	NULL
activation	NULL
.	NULL

Immunity	NULL
6:165	NULL
.	NULL

Mercurio	NULL
,	NULL
F.	NULL
,	NULL
H.	NULL
Zhu	NULL
,	NULL
and	NULL
B.	NULL
W.	NULL
Murray	NULL
.	NULL

1997	NULL
.	NULL

IKK-1	NULL
and	NULL
IKK-2	NULL
:	NULL
cytokine-activated	NULL
IxB	NULL
kinases	NULL
essential	NULL
for	NULL
NF-KB	NULL
activation	NULL
.	NULL

Science	NULL
278:860	NULL
.	NULL

Regnier	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
H.	NULL
Y	NULL
.	NULL

Song	NULL
,	NULL
X.	NULL
Gao	NULL
,	NULL
D.	NULL
V.	NULL
Goeddel	NULL
,	NULL
Z.	NULL
Cao	NULL
,	NULL
and	NULL
M.	NULL
Rothe	NULL
.	NULL

1997	NULL
.	NULL

Identification	NULL
and	NULL
characterization	NULL
of	NULL
an	NULL
IB	NULL
kinase	NULL
.	NULL

Cell	NULL
90:373	NULL
.	NULL

Koretzky	NULL
,	NULL
G.	NULL
A	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
role	NULL
of	NULL
Grb2-associated	NULL
proteins	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
18:401	NULL
.	NULL

Karin	NULL
,	NULL
M.	NULL
,	NULL
Z.	NULL
G.	NULL
Liu	NULL
,	NULL
and	NULL
E.	NULL
Zandi	NULL
.	NULL

1997	NULL
.	NULL

AP-1	NULL
function	NULL
and	NULL
regulation	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

9:240	NULL
.	NULL

Ravichandran	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
S.	NULL
J.	NULL
Burakoff	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
adaptor	NULL
protein	NULL
Shc	NULL
interacts	NULL
with	NULL
the	NULL
Interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
receptor	NULL
upon	NULL
IL-2	NULL
stimulation	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:1599	NULL
.	NULL

Bacuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1996	NULL
.	NULL

NF-kB	NULL
:	NULL
ten	NULL
years	NULL
after	NULL
.	NULL

Cell	NULL
87:13	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL

